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1 Abstract 
The immune system consists of two main components. The first is the innate immune 
system, which acts as the first line of defense in a rapid and unspecific manner. The 
second is the adaptive immune system, which is based on receptor rearrangement 
after the first encounter with a pathogen. It is responsible for a strong, sophisticated, 
highly-specific and long-lasting response. These responses encompass pathogen 
specific antibodies (Abs) and cytotoxic T cells. This complex system of adaptive 
immunity is orchestrated by specialized CD4+ T cells, the so-called T helper (Th) 
cells. These cells were classically divided into two major subsets by their functions. 
The Th1 cells that are mainly responsible for defense against intracellular pathogens, 
and the Th2 cells that are needed to initiate efficient production of Abs against 
extracellular pathogens and helminths. Only a few years ago a third subset named 
Th17 was discovered, which is characterized by the production of the cytokine 
interleukin-17 (IL-17). This subset is known to be important for optimal clearance of 
certain pathogens, but can also contribute to autoimmune and inflammatory 
diseases. However, up to now there is fragmentary knowledge about Th17 cells, 
especially regarding their induction following infection and vaccination. Depending on 
the specific pathogen, the appropriate Th phenotype should be stimulated in order to 
trigger optimal protective immunity against infection. Therefore, it is essential to 
elucidate under which circumstances a particular Th cell type is induced (e.g. after 
vaccination). Previous studies suggest that antigen (Ag) dose plays an important role 
in Th1/Th2 polarization. 
 
In this work, in vitro and in vivo studies using wild type and transgenic mouse models 
were performed to get insights into the mechanisms of Th cell induction, particularly 
in relation to the Ag dose. In vitro proliferation assays comparing antigen dose 
dependent Th polarization in cells from DO11.10 and OTII T cell receptor (TCR) 
transgenic mice (all TCRs in these animals are specific for ovalbumin [OVA]) 
revealed striking differences in Th17 induction between the two mouse strains. In 
contrast, no differences were detected with respect to Th1 and Th2 polarization. 
DO11.10 cells show an induction of Th17 cells at low and high Ag doses, whereas 
OTII cells polarize to Th17 cells exclusively in the presence of high Ag doses. 
Experiments with fluorescent labeled Ag identified differences in TCR affinity to the 
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Ag as one reason for the observed phenomenon. In vivo immunizations of wild type 
mice with the model Ag OVA led to Th17 induction at low Ag doses. Recent studies 
provided evidence that Th17 cells are important in fighting influenza infections. 
Inspired from these results, immunizations with H5N1 virosomes followed by an 
H5N1 viral challenge were performed to investigate whether low doses of H5N1 
virosomes lead to increased Th17 immune responses and improved protection as 
compared to standard Ag dose immunizations. To extensively monitor Th responses 
in vaccinated animals a sophisticated 9 color staining panel for flow cytometry 
analysis was established, which also allowed assessment of the induction of 
polyfunctional T cells. The results revealed protection of mice immunized with low 
virosome dosage after challenge with the influenza virus. However, the number of 
Th17 cells was not increased in these animals, compared to those receiving higher 
doses. 
Since Th17 immune responses are not always beneficial for the host, as a secondary 
aim of this work activities were focused on the establishment of strategies to block 
Th17 induction at will. To this end, the specific blocking of Th17 induction by a 
pegylated derivate of α-galactosylceramide (αGCPEG) was investigated and 
dissected. In vitro and in vivo experiments demonstrated that natural killer T (NKT) 
cells released high amounts of interleukin (IL)-4 and interferon (IFN)γ post αGCPEG 
stimulation and subsequently blocked the induction of Th 17 cells. 
 
Taken together the results of this thesis contribute to a better understanding of Th 
biology, especially with respect to Th17 induction and blockage. Knowledge about Th 
polarization is a key for the development of tailored immune responses following 
vaccinations. It is expected that the tools and strategies established during this work 
will facilitate the development of vaccines able to stimulate tailored Th17 responses 
to promote optimal protection against infection. 
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2 Introduction 
2.1 The immune system 
Every higher organism faces daily potential harmful pathogens. During evolution a 
number of defense mechanisms evolved, which are able to protect the host from 
these pathogens. In vertebrates the first line of defense are physical barriers, like the 
skin or mucosa with its antibacterial peptides, fatty acids, enzymes and low pH value 
which hinder microbial pathogens to enter the body. In addition, the immune system 
(a network of specialized cells, molecules, tissues and organs) controls the 
pathogens that have penetrated body barriers. The immune system can be 
subdivided into the innate and the adaptive immune systems, which have different 
cellular components and functions (Fig. 1) [1, 2]. 
 
 
Fig. 1: Cellular components of the immune system. Immune cells are classified as innate or adaptive 
immune cells based on their function. γδ T cells and natural killer T (NKT) cells are part of both arms of the 
immune system since they show characteristics of innate immune cells but express T cell receptors which are 
specific for adaptive immune cells (modified from [3]). 
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2.1.1 The innate immune system 
The task of the innate immune system is the defense against invading pathogens 
without prior antigen stimulation. This part of the immune system plays an 
fundamental role in early stages of immune reactions and it is the first line of defense 
against infection. In fact, without the innate immune system the host would die a few 
hours after infection. Once a pathogen has crossed the physical barriers, different 
effector mechanisms are activated. The innate response includes soluble proteins 
and bioactive small molecules that either directly act on the pathogens (e.g. 
complement proteins, defensins and ficolins) or are released from cells upon 
activation (e.g. cytokines and chemokines), to subsequently recruit and activate 
additional immune cells [1, 4]. Constituent parts of the innate immune system are 
hematopoietic cells like macrophages, dendritic cells (DCs), mast cells, neutrophils, 
eosinophils, natural killer (NK) cells, and natural killer T (NKT) cells [2]. These cells 
express the so-called pattern recognition receptors (PRR), which are able to 
recognize highly conserved components of pathogens, the pathogen-associated 
molecular patterns (PAMPs) [5, 6]. PRR are a large group of receptor molecules, 
including toll like receptors (TLRs), complement receptors, C-type lectins, and 
nucleotide-binding oligomerisation domain (NOD) receptors [7-9] and detect a wide 
range of non-mammalian structural motifs found in and on microbial pathogens (e.g. 
lipopolysaccharides [LPS], dsRNA and certain DNA motifs). The innate immune 
system can distinguish with these receptors between self and non-self and/or 
dangerous molecules. Upon sensing potential harmful motifs signaling cascades are 
started, which result in the activation of an appropriate immune response [1]. 
 
Most cells of the innate immune system have the ability to take up pathogenic 
microbes by phagocytosis or micropinocytosis. Inside the cell the phagosomes are 
fused with lysosomes to kill the engulfed microbes. Macrophages and especially DCs 
are able to process the uptaken antigens (Ags) and load the resulting peptides on 
either major histocompatibility complex class II (MHC class II) or, in case of cross-
presentation MHC class I molecules. These MHC molecules are transported then to 
the cell surface and present the loaded peptides to other immune cells. Due to this 
function these cells are called antigen-presenting cells (APCs) [10]. 
DCs are derived from bone marrow progenitor cells and represent a heterogenic 
group of innate immune cells with subsets, which possess different morphologies, 
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phenotypes and functions [11]. Immature DCs start a maturation and activation 
process after being stimulated by either PRRs binding to PAMPs or Ag uptake. 
During this process the expression of Ag presenting molecules (MHC class I and 
class II), co-stimulatory molecules (e.g. CD40, CD80, CD86, OX40L) and adhesion 
molecules (e.g. CD11a, CD11b, CD54, CD58) is up-regulated [12, 13]. Mature 
activated DCs induce both innate and adaptive immune responses by the production 
of cytokines (e.g. IL-12, IL-15, IL-18, type I interferons [IFNs], tumor necrosis factor 
alpha [TNFα]), and the activation and expansion of lymphocytes [14-16]. The ability 
of DCs to activate a large variety of different immune cells is the key for their in 
linking the innate and the adaptive immune system. 
 
2.1.2 The adaptive immune system 
The innate immune system reacts fast and quite unspecific to everything that fulfills 
at least one of the requirements “foreign” and/or “dangerous” (see 2.1.1). This 
response is not only unspecific, but also short lasting in nature. In contrast, the 
adaptive immune system requires some time to answer to a potential pathogen in a 
highly specific manner, including the establishment of immunological memory. 
The adaptive immune system can be subdivided into two parts, the humoral and the 
cellular arm, which collaborate to protect the host against threats from inside and 
outside the body. 
 
The humoral immunity is the defense mechanism of choice against extracellular 
pathogens and toxins, but is also needed for clearance of certain intracellular 
pathogens and viruses. Humoral immunity is mediated by immunoglobulins (Ig), also 
called antibodies (Abs). They are secreted by B cell derived plasma cells upon 
stimulation/activation. Abs from plasma cells confer protection by (i) neutralization, (ii) 
opsonization and (iii) complement activation. Neutralizing Abs bind to bacteria and 
viruses in the extracellular space and prevent their attachment to the cell surface. 
Bacterial toxins are also fought by neutralizing Abs, which block their biological 
activity and hinder them to enter host cells [1, 17]. To enhance the killing of 
pathogens, their surface is coated with Abs to mark them as a foreign target. This 
process is called opsonisation. The constant region of an Ab binds to the Fc receptor 
on phagocytic and NK cells which leads either to phagocytosis or in the case of NK 
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cells to so-called antibody-dependent cell-mediated cytotoxicity. The underlying 
mechanism is comparable to the action of cytotoxic T lymphocytes (CTLs), involving 
the release of cytoplasmic granules containing perforin and granzymes [1, 18]. The 
third mechanism of action of Abs is the activation of the complement system after 
binding to a pathogen. Complement proteins can enhance the opsonization process, 
recruit phagocytic cells to the site of infection or even directly lyse the pathogen [1, 
7]. 
 
Naïve B cells circulate through blood, lymph nodes (LNs) and spleen and express 
IgM and IgD on their cell-surface, which in turn act as their Ag receptors. When 
encountering multivalent Ags, the initiation of B cell activation takes place by 
clustering the Ag receptors. The next step is an increased expression of specific 
markers (e.g. MHC class II, CD80/CD86), which are needed for the subsequent 
interaction with T helper (Th) cells to deliver the secondary signal for activation. Th 
cell secreted cytokines are able to stimulate the proliferation of B cells, their 
differentiation into plasma cells and subsequently the formation of memory cells [1, 
19]. After first contact with a pathogen, plasma cells produce IgM isotype Abs, which 
have normally quite low affinity to the Ag. However, due to the formation of 
pentamers, IgMs can compensate their low affinity with a high avidity and the ability 
to trigger efficiently the complement system. B cells can undergo somatic 
hypermutation, gene conversion and class switch, which subsequently leads to the 
production of highly specific Abs of the IgG and IgA subclasses [1, 20]. 
 
The second part of the adaptive immune system is the T cell mediated immunity. This 
system consist mainly of immune cells characterized by their α/β T cell receptor 
(TCR) expression, which recognize peptide Ags bound to MHC class I or II 
molecules. These α/β-T cells differentiate into different subsets: (i) CD8+ T cells 
which act primarily via direct killing of cells infected with intracellular microbes, and 
(ii) CD4+ T cells which orchestrate and regulate the cellular and humoral immune 
responses. Another small subset of α/β-T cells is characterized by by CD4- CD8- 
NK1.1+ phenotype. The so-called NKT cells recognize glycolipid antigens presented 
by the CD1d molecule and show immune-regulatory properties by the secretion of 
cytokines, such as IFNγ, IL-4, granulocyte-macrophage colony stimulating factor 
(GM-CSF) or TNFs. During the development of T cells the TCR complex is formed by 
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combination of variable α and β chains. Moreover, each chain can even undergo 
gene rearrangement which leads to the generation of a huge diversity of different 
TCRs with specific affinity to almost all possible Ag structures. However, all T cell 
receptors on one T cell are identical [1, 2]. 
 
Naïve T cells need three signals to become activated. First the binding of the TCR 
and the CD4/8 molecule to the specific Ag presented either on MHC class II for CD4+ 
or on MHC class I for CD8+ cells. TCRs are also associated with the CD3 complex 
which transduces the activation signal when the TCR binds to antigen-MHC 
complexes. Second, T cells require for full activation the binding of co-stimulatory 
molecules, such as CD28, and as third signal the binding of cytokines released by 
APC. The combination of all three signals results in the activation of genes that 
control lymphocyte proliferation and differentiation. All signals for activation of CD4+ T 
cells can be delivered by APCs like DCs, whereas for the activation of CD8+ T cells 
an additional support of Th1 cells in most cases is needed. When DCs contact T 
cells, the so-called immunological synapse (IS) is formed. This is a specialized 
interface for information exchange where interacting molecules cluster. The DC/ T 
cell contact normally takes place in highly organized lymphatic tissues like the lymph 
nodes (LN), where the chances of encounter between T cells with corresponding 
TCR to Ag presented by DCs is dramatically increased [1, 2, 21, 22]. Activated 
antigen-specific CD8+ T cells differentiate into CTLs, able to kill infected host cells or 
cancer cells in a direct contact dependent manner. Thereby, target cells are 
specifically recognized by CTLs due to the display of Ags on a MHC class I molecule. 
Upon binding to a target cell, CTLs mobilize cytolytic granules containing mainly 
perforin and granzymes. The content of the cytolytic granules is secreted and 
granzymes enter the target cells via perforin-formed pores. Inside the target cell 
granzymes trigger signal cascades which induce apoptosis in the target cell. In 
addition, activated CD8+ T cells secrete a variety of cytokines (e.g. IFNγ and TNFα) 
which influence and support the function of other involved immune cells [1, 2, 23, 24]. 
 
The largest T cell population is characterized by the CD4+ phenotype. These cells 
direct and regulate the immune responses after binding to Ag peptides presented on 
MHC class II molecules on APCs. In Fig. 2 the four main subsets are presented, 
which can develop from a naïve CD4+ T cell upon encounter of an Ag presented by 
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APC. The circumstances and mechanisms leading to an antigen specific response 
are still not completely known and considerable scientific effort is invested into this 
field. This work focuses on the development of Th subsets, especially the Th17 
subset, mainly with respect to the influence of the Ag priming dose. Th1 and Th2 
cells are discussed in section 2.1.3, whereas section 2.1.4 focusses on Th17 cells. 
 
 
Fig. 2: Differentiation of naïve CD4
+
 T cells to effector subsets. The possible differentiation routes of 
a naïve CD4
+
 T cell after stimulation by Ag loaded DC is shown. Effector subsets are displayed with their lineage 
specific transcription factor and secreted cytokines. The main cytokines from each subset are marked with a red 
box (modified from [25].  
 
The regulatory T (Treg) cell subset is characterized by the expression of the 
transcription factor forkhead box P3 (FOXP3), high expression of CD25 in most 
cases and the production of IL-10 and TGFβ [26-29]. Their main function is the 
regulation or modulation of an induced immune response. This results in tolerance 
and prevents an overreaction of other immune cells, which would lead to severe 
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inflammations or autoimmune diseases, as observed in individuals with mutations in 
the FOXP3 gene [28, 30-33]. Furthermore, the establishment of a healthy immune 
homeostasis in newborns as well as the return to this homeostasis state after 
clearance of a pathogen is facilitated by Tregs (reviewed in [34]). The interaction of 
Tregs with Th cells and their regulatory function is discussed in the sections 2.1.3 
and 2.1.4. 
 
The differentiation of a naïve CD4+ T cell to a Treg can take place in either (i) the 
thymus in the presence of self Ag, leading to thymic (t)Tregs or (ii) the periphery in 
contact with non-self Ags like allergens, food or the commensal microbiota, leading to 
induced (i)Tregs. The induction of tTregs depends mainly on the strength of TCR 
signaling and the presence of TGFβ and especially IL-2 in the microenvironment (Fig. 
3). Naïve T cells with TCRs which show a high affinity to Ags presented on DCs in 
combination with low co-stimulation at the same time (e.g. potential allergens or Ags 
from commensal microbes) develop to iTregs (reviewed in [35]). 
 
 
Fig. 3: Treg differentiation in the thymus as a result of TCR signal strength and the availability 
of IL-2. High TCR affinity to self Ag leads either to depletion of the T cell or differentiation to a Treg. Medium 
TCR affinity can lead to depletion, often Treg differentiation or a conventional T cell. Low TCR signaling strength 
elicited by self Ag leads in most cases to conventional T cells and rarely to Tregs. The fate of the T cell is in all 
three cases controlled by the availability of IL-2. [35] 
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2.1.3 T helper 1 and T helper 2 cells 
T helper cells were first described in 1986 and divided into Th1 and Th2 cell based 
on their ability to produce either IFNγ or IL-4 [36]. These two cell subsets can be 
further characterized by lineage specific transcription factors and signal transducers. 
Th1 cells express T-bet and are dependent on STAT1 and 4 signaling, which are the 
major transducers in IFNγ and IL-12 signaling [37-42]. Th2 cells express the GATA3 
transcription factor and need the support of STAT5 and 6 signaling (IL-2 and IL-4 
pathways) for differentiation and effector function [43-47]. 
 
As mentioned before, the immune response against intracellular pathogens is mainly 
controlled and mediated by Th1 cells and their ability to produce IFNγ, IL-2 and 
TNFα. IFNγ stimulates macrophages to ingest and kill microbes and further promotes 
production of IgG2a and IgG3 subclasses by B cells in mice. In combination with IL-
2, IFNγ activates CTLs and plays a critical role in T cell memory formation, whereas 
TNFα is a primary inducer of inflammation [48-51]. In contrast, Th2 cells produce IL-
4, IL-5, IL-10 and IL-13 and coordinate the humoral immune response, especially 
against extracellular pathogens including helminthes. IL-4 mediates the IgE class 
switch in B cells and is involved in a positive feedback loop in Th2 differentiation, 
whereas recruitment and activation of eosinophils is controlled by IL-5. The 
production of IL-10 has anti-inflammatory effects, blocks Th1 differentiation and 
activates B cells. IL-13 plays an important role in host protection against helminthes 
and B cell activation. Direct cell-cell contact of Th2 and B cells, together with the 
secretion of IL-4, IL-10 and IL-13 lead to the activation, proliferation and 
differentiation of B cells, which in turn results in the production of highly specific 
neutralizing Abs [1, 49, 52-57]. It is known that some cells express Th1 and Th2 
cytokines at the same time in various combinations [58]. However, the numbers of 
these few “mixed” Th cells are negligible, as compared to the vast majority of clearly 
discriminable Th cells. 
Another point to mention is the fact that abnormal or uncontrolled Th responses can 
lead to severe health problems like chronic inflammation due to delayed type 
hypersensitivity caused by Th1 or asthma in the case of Th2 [59, 60]. Thus, the 
“right” type of Th response is crucial for the host when challenged with a pathogen, 
as shown by infections with persisting intracellular parasites of the genus 
Leishmania. These parasites can cause leishmaniasis, an illness with symptoms 
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ranging from small and local cutaneous inflammation, through widespread skin 
lesions which resemble leprosy, up to systemic infections associated with failure of 
inner organs and death [61]. Upon infection with Leishmania major most inbred 
mouse strains like C57BL/6 show a Th1 dominated immune response and are 
resistant or recover very fast from the parasite. In contrast, BALB/c mice fail to 
establish a protective Th1 immune response. The induced Th2 driven humoral 
immune response is not protective and leads finally to death of mice [62]. This 
remarkable example of mounting different Th responses upon infection with the same 
pathogen illustrates an important challenge in vaccine design. It is not enough to use 
just the “right” formulation of Ag epitopes, but also to promote the right type of 
response. Often Ags need to be co-administered with immune modulators or 
adjuvants to promote an immune response of the appropriate strength and type in 
order to confer protection. This leads directly to the question of how Th differentiation 
is induced and controlled. 
 
As described in section 2.1.2, the combination of three signals provided by APCs is 
required to start activation and differentiation of naïve CD4+ T cells. The key 
information to understand this process is that all three signals are not just simple 
events, but rather complex integrated processes in terms of signal strength, duration, 
composition and interaction [63-65]. The consequence of this is that differentiation of 
Th cells is mainly controlled by innate immune cells, especially DCs, since T cells 
only differ in their TCR and their affinity to presented Ags. DCs express many 
different PRRs which trigger different signaling pathways when binding to PAMPs. 
Thus, they react with different patterns of co-stimulatory molecule expression and 
cytokine release in response to different pathogen classes [1, 52, 65, 66]. The 
influence of cytokines on polarization of Th differentiation is almost elucidated. Th1 
cell induction is dependent on the presence of IFNγ and IL-12, and for clonal 
expansion on IL-2. Once induced, Th1 cells produce IFNγ and IL-2 by themselves 
which act in an autocrine fashion. In contrast, polarization to Th2 cells mainly 
requires IL-4 and to a lesser extent IL-2, showing the cells an autocrine IL-4 feedback 
loop [67-69]. The cytokines secreted by one Th type suppress directly the 
differentiation of naïve T cells to the other Th phenotypes (e.g. IFNγ blocks Th2 
differentiation, whereas IL-4 and IL-10 block the induction of Th1 cells) [52, 70]. The 
cross-regulation of Th1/2 and Th17 cells by cytokines is discussed in section 2.1.4. It 
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is known that also Tregs are able to influence the induction of Th cells via cytokines. 
This can be performed by different mechanisms: (i) indirectly, by interacting with DCs 
to inhibit their production of Th polarizing cytokines [71-73], (ii) by expression of high 
levels of CD25 (a subunit of IL-2 receptor) to deplete the available IL-2 in the 
microenvironment [74], and (iii) by release of cytokines (e.g. TGFβ and IL-10), which 
directly block Th differentiation [75, 76].  
 
Beside cytokines, co-stimulatory molecules are responsible for shaping the Th 
immune response. The major co-stimulatory molecule on T cells for activation, CD28 
with its binding partners CD80 and CD86 expressed on APC, was shown to influence 
Th polarization. Not only the signal strength and duration are important (stromg and 
long-lasting co-stimulation favors Th2 polarization [77]), but also the ratio between 
CD80 and CD86 on the APC is important (CD80 directs towards Th1 while CD86 
toward Th2 [78]). 
Already the strength of the primary signal for T cell activation, binding of TCR to 
Ag/MHC class II complex itself, directs the fate of a naïve T cell. When talking about 
signal strength against the background of TCR two points have to be considered: (i) 
affinity of the TCR to the complex of Ag peptide presented on MHC class II molecule, 
and (ii) the Ag dose. Naïve CD4+ T cells expressing a transgenic TCR show a Th1 
dominated polarization upon stimulation with the corresponding peptide, whereas 
stimulation with a low-affinity altered peptide ligand (APL) results in a Th2 
differentiation [79, 80]. Corresponding results were obtained when changing single 
residues of the TCR responsible for peptide binding [81]. As expected, also the Ag 
dose influences the signal strength and, subsequently, also Th development. In 
1995, two independent in vitro studies with TCR transgenic T cells showed induction 
of Th2 or Th1 cells when low or high doses of Ag were used, respectively (Fig. 4 and 
Fig. 5). Hosken et al. showed in their study with cells from DO11.10 TCR transgenic 
mice and OVA-peptide AA323-339 an additional raise of Th2 cells when adding very 
high Ag doses to the culture (Fig. 5) [82, 83]. An explanation for these findings is the 
increased Erk activation after strong TCR stimulation. This leads in turn to inhibition 
of GATA3, consequently weaker Th2 induction, and higher frequencies of Th1 cells 
[77]. In contrast, the occurrence of Th2 cells at very high Ag doses can be explained 
by STAT6 independent Th2 differentiation which is driven by high levels of IL-2 and 
STAT5 signaling [84]. Consistent with these results, in vivo studies with immunogenic 
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peptides demonstrated a Th1 polarization with high and Th2 polarization with low Ag 
doses [79, 85]. 
It has to be kept in mind, that the Ag dose will not only affect the amount of presented 
Ag by DCs but also influence the level of activation and co-stimulatory molecules 
expressed by DCs. This is even more influenced when the titrated “Ag” is a living 
pathogen or whole cell extracts, since the amount of delivered PAMPs will also 
influence the outcome of the immune response [86]. 
 
 
Fig. 4: Cytokine secretion by TCR transgenic CD4
+
 T cells primed with different Ag doses. 
Naïve TCR transgenic CD4
+
 T cells were primed with different doses of the corresponding Ag peptide in the 
presence of DCs and restimulated after 5 days. ELISA was performed to measure cytokines in the culture 
supernatant. (A) Amount of secreted IFNγ. (B) Amount of secreted IL-4. (modified from [82]) 
 
 
Fig. 5: Cytokines released by TCR transgenic DO11.10 T cells after priming with different 
dosages of OVA-peptide AA323-339. Levels of IL-4 and IFNγ in cell culture supernatants after re-
stimulation of naïve T cells primed with different Ag peptide doses during 5 days in presence of DCs (modified 
from [83]). 
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2.1.4 T helper 17 cells 
In 2005, the discovery of a 3rd Th subset changed the dogma of regulation of 
immune responses by Th cells [70]. The new lineage was named Th17 and is 
characterized by the ability to secrete mainly IL-17A, IL-17F and IL-22 [70, 87]. 
Thereby, IL-17A and IL-17F are able to form homo- and hetero-dimers (IL-17A/A, IL-
17-F/F and IL-17A/F). This study was focused on the action IL-17A/A and IL-17A/F 
since these members of the IL-17 family cover by far most effector functions and 
show similar biological properties as IL-17F/F [87, 88]. Thus, “IL-17” will stand for IL-
17A in the following, since IL-17A/A and IL-17A/F are recognized by the same Ab 
against IL17-A. 
 
As the other Th subsets, also Th17 cells show the expression of a lineage 
characteristic transcription factor, namely RORγt [89] and are dependent on the 
STAT3 signaling pathway. STAT3 is the major signal transducer for IL-6, IL-21 and 
IL-23, as well as responsible for the induction of IL-23R and subsequent production 
of IL-17 [90-92]. The cytokines secreted by Th17 cells fulfill different functions in the 
host. IL-17 induces many pro-inflammatory molecules, such as IL-6 and IL-8, and 
has an important role in the induction of inflammatory immune responses [93]. 
Recruitment of neutrophils as well as the induction of anti-microbial peptides (e.g. β-
defensins and lipocalin2) is also facilitated by IL-17. Receptors for IL-17 are 
expressed ubiquitously, with particularly high levels in hematopoietic tissues and in 
cells of the liver, kidney, prostate and joints [93-95]. IL-22 has bipolar functions; it 
induces tissue inflammatory reactions, as well as enhanced expression of tissue 
protective genes and anti-microbial peptides [96]. Experimental data suggest that 
inflammatory functions are induced in combination with IL-23 [97], whereas protective 
effects are observed mainly in acute liver and intestine inflammation [98, 99]. 
 
Different studies showed that Th17 cells are involved in the induction and 
progression of many diseases linked to autoimmunity or deregulated immunity (e.g. 
rheumatoid arthritis [RA], multiple sclerosis [MS], inflammatory bowel disease [IBD], 
asthma and psoriasis) [100]. For example, in RA, IL-17 stimulates by itself and in 
conjunction with TNFα and IL-1β various cell types to induce inflammation by 
enhanced production of cytokines, chemokines and destructive mediators, as well as 
promotion of influx of neutrophils and monocytes, which further increase 
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inflammatory responses [101-103]. The observed chronic inflammation of joints and 
bone destruction in RA induced by Th17 cells [101] is in accordance with the 
increased expression of IL-17R in joints. For MS and the murine homolog 
experimental autoimmune encephalomyelitis (EAE), it was shown that especially high 
levels of IL-17A are involved in neuro-inflammation and high clinical scores for 
disease progression, whereas neutralization leads to delayed disease progression or 
even partial recovery [104-108]. Although the exact role of Th17 cells in MS/EAE is 
not yet fully understood, one possible mechanism is the disruption of blood-brain-
barrier and subsequently inflammation of the central nervous system as shown by 
Kebir et al. [109]. In IBD the situation is not as clear as in the examples before. 
Patients with ulcerative colitis or Crohn’s disease (two forms of IBD) show high levels 
of IL17A in the mucosa and serum, corresponding to inflammatory progression [110, 
111]. In contrast, in mouse models for IBD the results are contradictory, some studies 
showed a positive effect of IL-17 neutralization [108, 112], whereas others showed a 
more severe progression of disease after neutralization of IL-17 or when ll-17a 
knockout mice were used [108, 113]. An explanation for this might be differences in 
the mouse gut microflora between different labs, which are in turn able to influence 
the IL-17 pathway during the IBD process [114]. 
 
In contrast, Th17 immune responses can also be beneficial or even needed. 
Protection against many pathogens (e.g. Candida albicans, Borrelia ssp., 
Helicobacter pylori, Klebsiella pneumoniae, Citrobacter rodentium, Salmonella spp., 
Mycobacteria, Bordetella ssp., Influenza [115]) is facilitated or rely on a Th17 directed 
immune response. Huang et al. showed in IL-17RA deficient mice an increased 
susceptibility to systemic C. albicans infection [116]. Patients with hyper IgE 
syndrome or chronic muco-cutaneous candidiasis have impaired Candida specific 
Th17 responses and showed dramatically increased susceptibility for mucosal C. 
albicans infections [117, 118]. In Borrelia infection, Th17 cells are induced and their 
signature cytokines levels are increased. Th17 cells seem to have a beneficial effect 
in early protection, whereas IL-17 was shown to lead to more severe destructive 
arthritis if a chronic Borrelia infection was established [119-121]. A clearly protective 
effect of Th17 cells in mouse model was observed in K. pneumoniae infections, 
where both cytokines, IL-17 and IL-22, were shown to be essential for survival upon 
challenge [122-124]. A recent study showed the protective effect of transferred Th17 
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cells upon challenge with an otherwise lethal dose of influenza virus. In addition, the 
inhibitory influence of IL-10 expression on Th17 development during influenza 
infection results in a negative effect on survival [125]. Thus, IL-10 as a cytokine 
produced by Th2 and Tregs is not only able to inhibit the induction of Th1, but also of 
Th17 cells. 
 
It is known, that the induction of Th17 cells is influenced by different factors, as it is 
the case for Th1/2 cells (see section 2.1.3). Also for Th17 development, the cytokine 
milieu has a huge impact. The presence of IL-6 contributes to polarization to Th17 
cells and since the IL-6R is expressed at high levels especially in naïve T cells, IL-6 
seems to have a key role in Th17 development [65, 126, 127]. In addition the TGFβR 
is highly expressed in naïve cells and the presence of TGFβ in low levels was shown 
to polarize naïve cells towards Th17, whereas high levels of TGFβ direct to the Treg 
lineage [35, 128]. As the other Th subsets, also Th17 cells seem to be regulated by 
an autocrine feedback loop, which is driven by IL-21 in Th17 cells. This cytokine is 
not only produced by Th17 cells, but also by many other cell types and is able to 
promote Th17 development in an autologous way while it blocks the production of 
IFNγ and hence Th1 polarization [65, 126, 129, 130]. The cytokine IL-23 is not 
needed for induction but crucial for survival of Th17 cells [131].The differentiation to 
Th17 cells can be inhibited by all other CD4+ T cell subsets by the production of their 
main cytokines (IL-2, IL-4, IL-10 and IFNγ), which trigger the signaling pathways that 
would normally induce Th1/2 or Tregs and subsequently block Th17 differentiation 
[91, 125, 132-134]. These findings support the fact that uncontrolled Th17 immune 
responses can lead to severe autoimmunity and chronic inflammation. 
 
Not only cytokines but also other soluble molecules influence Th development. The 
all-trans retinoic acid (ATRA) reduces the expression of IL-6R and IL-23R and is able 
to induce Tregs development [135-138]. Both effects constrain Th17 cells, but since 
the receptor for ATRA is not expressed on naïve T cells ATRA does not seem to play 
a critical role in the initialization of polarization of Th cells, but rather in ongoing Th 
differentiation [138, 139]. The varying levels of aryl hydrocarbon receptor (AhR) 
agonists in cell culture medium from different suppliers have strong influence on 
Th17 polarization, since high levels of Ahr agonists are needed for optimal induction 
[140]. Beside natural sources, AhR agonists are also found in cigarette smoke and 
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industrial contaminants and may play a role in the raise of autoimmune diseases, 
which correlates with the industrial use of hydrocarbons [65, 140]. 
 
Beside the cytokines and other soluble factors present in the microenvironment, the 
binding of co-stimulatory molecules at the time point of T cell activation is important 
for the fate of naïve T cells. CD28, the main transducer for secondary signaling in T 
cell activation, is initially needed for Th17 polarization, whereas prolonged CD28 
signaling results in inhibitory effects [107, 141]. The binding of the inducible co-
stimulatory molecule (ICOS) was shown to induce strong Th17 activation. 
Interestingly, ICOSL is expressed in high levels on cells of mucosal tissues and it is 
known that mucosal application of antigen leads to Th17 induction [142]. It is 
discussed that ICOS-ICOSL interaction is involved in this differentiation process [107, 
142-144]. Furthermore, the binding of CD40-CD40L leads to a crosstalk between T 
cell and DC, and subsequently stimulation of IL-6 production by DCs, an important 
factor for Th17 induction, as mentioned before [145]. In contrast, earlier studies 
showed the importance of CD40 co-stimulation in Th1 differentiation [146, 147]. An 
explanation for these contradictory observations might be the fact that the level of 
CD40L expression is regulated by the Ag dose in vitro [148]. 
 
This fact leads to the role of TCR signaling strength in Th17 induction. While the 
influence of TCR affinity to Ags presented on MHC class II is rather understood for 
Th1 and 2 cells (see section 2.1.3), no experimental data about Th17 cells is 
available in this context. The second factor influencing the signal strength is the 
antigen dose. In 2009, two studies reported that Th17 cells need relatively strong 
antigenic stimulation for their induction [149, 150]. These findings are in direct 
contrast to the fact that strong Th17 immune responses are elicited by intranasal 
application of Ag [142], which is normally linked to a poor uptake of Ag and leads to a 
reduction of the active Ag dose. Until now, there is no explanation for this dilemma. A 
recent publication demonstrates that low-strength T cell activation of human cells 
induce Th17 differentiation [151]. However, these findings were based only on in vitro 
data where cells were either stimulated with αCD3 Abs or with superantigen. Both 
methods differ from the natural process of TCR binding to peptide Ags presented by 
MHC class II molecules and can lead to abnormal T cell behavior, due to the 
triggering of unusual signaling pathways [152]. 
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Taken all records together, the current knowledge on Ag dose dependent induction of 
Th17 cells, especially in combination with polarizing cytokines, is very limited and 
needs further investigation. Thus, the aim of this thesis is to answer some of the 
pending questions: 
 Why some studies showed induction of Th17 cells at weak TCR stimulation, 
whereas others showed the need for high Ag doses? 
 In which way polarizing cytokines influence the Th17 differentiation in 
presence of different Ag doses? 
 What is the situation in vivo and how can these new insights be used to derive 
new vaccination strategies? 
 
As mentioned above, B and T cells can form Ag specific memory cells which can be 
reactivated upon reencounter of the same Ag. The immunological memory is an 
essential part for the efficiency of the adaptive immune system since it shortens the 
time to mount a highly specific and powerful adaptive immune response dramatically. 
This fast response allows the elimination of already encountered pathogens before 
they can spread and cause damage to the host. This mechanism is used in the 
process of vaccination and will be explained in the next section. 
 
2.2 Vaccination 
Worldwide about 13 million people die every year by the direct aftermath of infectious 
diseases, being the second leading cause of death [153]. Latest results in science 
show that infections with certain pathogens can also trigger cardiovascular diseases 
and even cancer. Taking these results under account would raise the number of 
victims from infections considerably above the previously mentioned number [154-
158]. 
 
Nowadays vaccination is still the most effective and cost-efficient method to prevent 
infectious diseases and the resulting deaths of millions of individuals [159]. The 
process of vaccination uses the ability of the immune system to form memory cells 
against already encountered pathogens. By administration of pathogen epitopes 
(Ags) in a non-harmful formulation the immune system is taught to build up a 
powerful defense against these Ags. This leads to a protection of the host from 
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disease when the real pathogen is encountered. The first scientific approach to use 
this mechanism was undertaken by Edward Jenner in the 18th century. He inoculated 
healthy humans with material from cowpox lesions, a quite harmless skin disease 
caused by Cowpox virus. After recovery these persons were then resistant to the life 
threatening infection with smallpox, caused by Variola virus. Jenner named this 
process “vaccination”, derived from the Latin root “vaccinus”, meaning “from cow” 
[160-163]. Louis Pasteur worked in the 19th century on developing safer strategies for 
vaccination. He introduced the concepts of attenuation, modification through passage 
and renewed virulence. His work helped to replace person-to-person vaccination with 
more or less defined vaccines which were less likely to transmit other diseases [164]. 
 
The early work from Jenner and Pasteur laid the basis for the control of ten major 
diseases (e.g. smallpox, diphtheria, tetanus, pertussis and poliomyelitis) by 
vaccination. The biggest success in this context was the eradication of smallpox in 
1980 and of Rinderpest, a cattle disease, in 2010 [160, 165, 166]. However, after 
decades of research and big advantages in developing improved and safer 
vaccination strategies, many live threatening diseases are still not controlled or are 
even spreading. Although big efforts are undertaken to develop vaccines against 
diseases like AIDS, HCV infection or malaria, researchers have not been really 
successful yet. Another challenging aspect today is the appearance of antibiotic 
resistances, as in the case of Mycobacterium spp. and Staphylococcus spp., and the 
fast spreading of easily transmitted respiratory infections able to lead to pandemic 
outbreaks like SARS (severe acute respiratory syndrome) caused by a corona virus 
or bird/swine flu caused by influenza viruses. These challenges make the research 
for new and/or improved vaccines essential, since from the present view vaccination 
is still the most valuable tool to prevent infectious diseases [159, 167]. 
 
Today there are different types of vaccines available. One group represents whole-
cell preparations, which can be either a live attenuated form of the pathogen or an 
inactivated/dead microbe. Attenuation is achieved by recombinant DNA technologies 
for creating strains which lack specific virulence genes or the more classical method 
of passaging the pathogen multiple times and selecting less virulent mutants. The 
advantage of live attenuated vaccines, like the ones used against measles or mumps 
is their ability to elicit strong humoral as well as cell mediated immune responses 
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through replication in the vaccinee. It has been shown that attenuated vaccines are 
save and do not cause a disease in healthy persons. In contrast, inactivated/killed 
vaccines cannot replicate and elicit in general weaker and shorter lived immune 
responses. This leads often to the requirement of boost vaccinations to establish a 
long lasting protective immunity. Inactivated/killed whole cell vaccines are generated 
by heat or chemical inactivation, or irradiation with UV light or gamma rays. An 
advantage is their safety even in immune compromised persons [168-172]. 
 
The second group of vaccines is composed of well-defined components, which can 
be purified from microbial components or expressed as recombinant Ags. Subunit 
vaccines, like the ones against diphtheria, tetanus, hepatitis B virus or papilloma 
virus belong to this group. The attractiveness of this approach is the low number of 
immunogenic targets, thereby maximizing the immune response against these 
molecules. To achieve protection it is essential to identify the main components of a 
pathogen which are able to confer protective immunity, and to include the identified 
Ags  into the vaccine formulation. The use of well-defined components in the 
formulation also improves the safety profile of the vaccinates. However, the overall 
safety features of such subunit vaccines represent also their limitation. Many 
pathogens alter their surface structures by mutation and escape by this mechanism 
immune responses directed against single targets [173, 174]. This might represent a 
problem for pathogens prone to mutation, since a limited number of Ags are induced 
in the formulation. 
 
All types of vaccines can be administered via different routes. The application route 
by itself directly influences the immune response in terms of Th phenotype and 
localization (local and/or systemic). This is especially important, since the first steps 
of protective defense have to take place at the initial entry site of pathogen invasion 
[142, 175]. Most of the currently available human vaccines are given by the 
parenteral/systemic route by injection (e.g. subcutaneous, intradermal or 
intramuscular). These three different injection routes lead to the uptake of Ag by 
different APC types. While in the skin many resident APCs, like the Langerhans cells 
are found which are able to initiate strong immune responses, under the skin or in the 
muscles only few resident APCs are found. Here the Ag is taken up in most cases by 
transient resident APCs or travels through the lymphatic system to the next draining 
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LN. In general, parenteral immunization mainly evokes systemic immune responses 
with very poor local protection. Thus, this route is especially suitable for vaccination 
against systemic infections, like hepatitis viruses [175]. 
 
However, almost all pathogens are either restricted to the mucosal membranes or 
need to breach them in order to spread and cause systemic infections. Thus, the 
stimulation of a local immune response at the potential infection site is a clear 
advantage, since it confers protection by early blocking of colonization and infection. 
In contrast, systemic vaccination only protects against disease (e.g. symptoms), 
being vaccinated individuals still prone to colonization and able to transfer the agent 
to other susceptible hosts. This local protection can be achieved by mucosal 
administration, since this immunization route induces not only local but also systemic 
immune responses. Especially intranasal application is easy and leads to local 
protection in the oral and nasal cavity, as well as in the genitourinary tract. Thus, this 
route can be recommending not only for vaccines against airborne pathogens, but 
also against sexually transmitted diseases [176-180]. An example for successful 
development of a vaccine administered by intranasal route is the live attenuated 
trivalent influenza vaccine [181, 182]. 
 
The drawback of intranasal vaccination is the poor immunogenicity of antigens 
delivered by this route. This is due to different factors: (i) Ag clearance (e.g. ciliar 
activity, entrapment in mucus, degradation by proteases), (ii) the existence of a local 
tolerogenic milieu, (iii) limited antigen delivery through the mucosa, or (iv) limited 
occurrence of APCs to take up the Ag. Thus, Ags should be delivered either by 
systems which are able to breach through the mucosal barrier or co-administered 
with suitable mucosal adjuvants [183].  
 
2.3 Adjuvants 
As described in section 2.2, Ags in defined subunit vaccines are less immunogenic 
when compared with live or whole cell component vaccines, which have built-in 
adjuvant properties. Beside the protective Ags, whole cell vaccines also encompass 
components acting as danger signals which activate the immune system [184]. Thus, 
weak immunogenic subunit vaccines need the help of immune stimulatory molecules, 
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the so-called adjuvants (lat.: adjuvare = to help) to enhance immunogenicity. Almost 
all subunit vaccines in the market include these molecules (e.g. alum, MF59 and 
ISCOM). An ideal adjuvant should strengthen, speed up and direct the immune 
response against the applied Ags in a well-defined manner, without having by itself 
immunogenic or reactogenic properties. In addition, it should be stable with respect 
to storage but also biodegradable, cheap and fast to produce [185]. 
 
Since adjuvants are a complete heterogeneous group of compounds they differ in the 
mechanisms by which they act and interact with different immune cells. One way is 
the creation of an antigenic reservoir which slowly releases the Ags over time (e.g. 
alum). In addition, adjuvants can act directly, for example by targeting Ags to APCs 
and subsequent promotion of Ag processing and presentation. Alternatively, 
adjuvants can also work indirectly by promoting a microenvironment which helps to 
modulate, enhance and direct the immune response against the Ags [174].  
In general adjuvants are divided into two classes, immune stimulants and vehicles or 
delivery systems. Immune stimulants like saponins, TLR ligands or bacterial toxins 
increase the response to Ags by acting directly on the innate immune system. In 
contrast, vehicles and delivery systems like mineral salts, emulsions or virosomes 
provide an optimized presentation of Ags to the immune system [172]. 
 
At the moment there are only eight formulations approved for use in human vaccines. 
These include alum, squalene-based emulsion, glycolipide monophosphoryl lipid A 
derived from LPS, cholera toxin subunit B, virus like particles and influenza 
virosomes [172, 174]. Since none of the approved adjuvants is “ideal”, there are 
some disadvantages like the low efficient induction of mucosal immune responses or 
the poor induction of CTL-mediated immunity [172, 186]. For these reasons, it is still 
important to search for new adjuvants which are able to overcome the described 
problems. In the pipeline of industry and research are at the moment new promising 
compounds, among others synthetic oligodesoxynucleotides containing 
unmethylated CpG motifs to trigger TLR9, IC31 that also triggers TLR9, MALP-2 a 
TLR2/6 ligand or saponins [172, 174, 187-191]. 
 
An interesting adjuvant with respect to the elicited Th phenotype in the immune 
response and its mechanism of action is α-galactosylceramide (αGC). This glycolipid 
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was first derived from the marine sponge Agelas mauritianus and later modified by 
pegylation to enhance its biological properties [192, 193]. It was shown that αGC has 
immune modulatory properties, leading to the activation of various cell subsets of the 
innate and adaptive immune system. APCs can present αGC by CD1d molecules to 
Vα14+ NKT cells which are activated upon binding and start to produce large 
amounts of IFNγ and IL-4 [194-198]. It was shown that activation of Vα14+ NKT cells 
leads to a Th2 biased immune response and blocks Th17 polarization [199].  
 
Other interesting candidates are the cyclic-di-nucleotides [200-202]. Among them, 
the bis(3’,5’)-cyclic dimeric adenosin mono phosphate (c-di-AMP), which was first 
described as a second messenger signaling for DNA integrity in Bacillus subtilis 
during sporulation [203]. Chemically seen, it is a small cycle of RNA, containing two 
bases linked to ribose and phosphate. Since c-di-AMP does normally not occur in 
higher organisms it acts as a PAMP and is sensed by binding to STING [201, 203, 
204]. It was shown that c-di-AMP promotes a local and systemic immune response 
with a Th1/Th17 dominated immune response when used as adjuvant in a murine 
system [202]. However, in contrast to CpG motifs, a robust Th2 component is still 
present. 
 
Influenza virosomes seem to be a promising combination of Ag carrier and immune 
stimulating adjuvant leading to local and systemic protection [205, 206]. For the 
production of virosomes, an influenza vaccine strain is propagated in chicken eggs 
and then inactivated (e.g. with beta-propiolactone or formaldehyde). Subsequently 
the surface glycoproteins and phospholipids are solubilized with the detergent 
octaethyleneglycol onododecylether and the influenza surface antigens 
hemagglutinin (HA) and neuraminidase (NA) are purified and mixed with lecithin. By 
step-wise removal of the detergent virosomes form spontaneously and the HA and 
NA viral antigens are incorporated into the phospholipid bilayer [207]. Similar to 
influenza virus, virosomes bind to host cells via HA and trigger endocytosis. Inside 
the endosome, the low pH value leads to HA-mediated membrane fusion and partial 
escape of virosomes to cytoplasm. Thereby, MHC class I restricted immune 
responses are stimulated. In parallel, HA and NA fragments are presented by MHC 
class II molecules and trigger CD4+ T cell activation [205]. 
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3 Aim of the study 
Most vaccines on the market trigger by a combination of Ag(s) and adjuvant in their 
formulation strong Th2 dominated immune responses to provide protection. As above 
mentioned, a newly discovered Th subset called Th17 has been reported to play an 
important role in combating certain infectious pathogens. However, their induction by 
vaccines is poorly understood and it was therefore not considered in the rational 
process of vaccine design. In this context, it has been shown that the antigen dose 
plays an important role for shaping Th1/Th2 subsets following immunization. 
 
Thus, the overall aim of this thesis was to clarify the impact of Ag dose on Th17 
induction and to investigate whether changes in Ag concentration of vaccine 
formulations can be exploited to tailor T cell responses. To this end, in vitro 
experiments with cells from TCR transgenic and wild type mice were performed to 
characterize Ag dose dependent induction of Th17 cells. The experiments 
investigated polarization (i) under normal culture conditions, (ii) in the presence of a 
polarizing cytokine milieu or (iii) by neutralization of Th17 blocking cytokines. In vivo 
immunization studies with the model Ag OVA were also performed to set up a model 
system of targeted Th17 induction. This system was subsequently transferred to a 
vaccination relevant setting in which the impact of Ag dose-dependent modulation of 
Th17 responses on protective immunity was addressed in vivo. This was achieved by 
using an influenza vaccine in combination with a murine viral challenge model. To 
obtain a complete in vivo characterization of the T cell responses, a complex 9-color 
staining panel for flow cytometry analysis was established during this study. 
 
It has been described that Th17 immune responses can correlate with detrimental 
outcome for the host after infection with certain pathogens. Therefore, the possibility 
to selectively shutdown Th17 induction after vaccination could represent a true asset 
for the development of certain vaccines. The adjuvant αGCPEG is able to induce Th2 
immune responses, but blocks Th17 induction. However, the mechanism of action 
was unknown. Thus, the second part of this work investigated the underlying 
principles of Th17 blockage by αGCPEG, as alternative approach to dose dependent 
fine-tuning of the elicited responses. To this end, in vitro experiments with murine 
NKT cells and in vivo immunization studies with wild type and NKT KO mice were 
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performed, which enable to characterize the underlying mechanisms of Th17 
blockage. It is expected that the knowledge and strategies established during this 
work will facilitate the development of vaccines able to stimulate tailored Th17 
responses. 
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4 Material 
4.1 Antibodies 
Table 1: List of used antibodies 
Antigen Clone Fluorochrome Company Cat.# 
CD3 500A2 V500 
Becton, Dickinson and 
Company (BD), USA 
560773 
CD3 17A2 APC 
eBioscience (eBio), 
Germany 
51-0032-82 
CD3 145-2C11 FITC BD, USA 553062 
CD3 17A2 unlabeled eBio, Germany 16-0032-86 
CD4 RM4-5 PE-Cy7 eBio, Germany 25-0042-82 
CD4 RM4-5 APC-Alexa750 eBio, Germany 27-0042-82 
CD8a 53-6.7 PB eBio, Germany 48-0081-82 
CD8a 53-6.7 FITC BD, USA 553031 
CD8a 53-6.7 PE BD, USA 553033 
CD11b M1/70 PE BD, USA 557397 
CD11c N418 FITC eBio, Germany 53-0114-82 
CD11c N418 PE eBio, Germany 12-0114-83 
CD11c N418 APC eBio, Germany 17-0114-82 
CD11c N418 APC-Cy7 eBio, Germany 25-0114-82 
CD25 PC61 PE BD, USA 553866 
CD28 37.51 unlabeled eBio, Germany 16-0281-86 
CD44 IM7 APC eBio, Germany 17-0441-83 
CD45R (B220) RA3-6B2 PE BD, USA 553089 
CD49b (DX5) DX5 PE BD, USA 553858 
CD62L MEL-14 FITC BD, USA 553150 
CD80 16-10A1 PE eBio, Germany 553769 
CD80 16-10A1 APC eBio, Germany 17-0801-82 
CD86 GL1 FITC BD, USA 553691 
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CD86 GL1 PE BD, USA 553692 
CD90.1 HIS51 PE-Cy5 eBio, Germany 15-0900-82 
CD90.1 HIS51 PE-Cy7 eBio, Germany 25-0900-82 
CD90.1 HIS51 PerCP-Cy5.5 eBio, Germany 45-0900-80 
CD90.2 53.2-1 FITC BD, USA 010041 
CD90.2 53.2-1 PE-Cy7 eBio, Germany 25-0902-82 
I-A
b/d
 M5/114.15.2 eFluor450 eBio, Germany 48-5321-82 
IFNγ XMG1.2 PE eBio, Germany 12-7311-82 
IFNγ XMG1.2 Alexa647 eBio, Germany 51-7311-82 
IFNγ XMG1.2 PB eBio, Germany 48-7311-82 
IFNγ R4-6A2 unlabeled eBio, Germany 16-7312-85 
IL-2 JES6-5H4 APC-Cy7 BD, USA 560547 
IL-2 JES6-1A12 unlabeled eBio, Germany 16-7022-82 
IL-4 11B11 APC eBio, Germany 17-7041-82 
IL-4 11B11 unlabeled eBio, Germany 16-7041-85 
IL-10 JES5-16E3 AlexaF700 eBio, Germany 56-7101-82 
IL-17A eBio17B7 FITC eBio, Germany 11-7177-81 
IL-17A eBio17B7 PE eBio, Germany 12-7177-81 
IL-17A eBio17B7 Alexa647 eBio, Germany 51-7177-82 
IL-17A TC11-18H10 V450 BD, USA 560522 
IL-17F eBio18F/0 PE eBio, Germany 12-7471-80 
IL-17F eBio18F/0 Alexa647 eBio, Germany 51-7471-80 
IL-22 1H8PWSR PerCP-eF710 eBio, Germany 46-7221-82 
NK1.1 PK136 APC eBio, Germany 17-5941-82 
TNFα MPG-XT22 eFluor450 eBio, Germany 45-7321-82 
TNFα MPG-XT22 PerCP-eF710 eBio, Germany 46-7321-82 
Vβ5.1/5.2 MR9-4 PE BD, USA 553190 
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4.2 Chemical compounds and reagents 
Table 2: Chemical compounds and reagents 
Chemical: Company: 
3-amino-9-ethyl-carbazole (AEC substrate kit)  BD Pharmingen, USA 
Acetic acid (CH3COOH) Merck, Germany 
Acetonitrile (CH3CN) Sigma-Aldrich, Germany 
Ampuwa
 
 Serumwerk, Germany 
Avidin-HRP (horseradish peroxidase) conjugated  BD Pharmingen 
Ammonium chloride (NH4Cl)  Merck, Germany 
Bovine serum albumin (BSA) Sigma-Chemie, Germany 
Brefeldin A Sigma-Chemie, Germany 
Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) Invitrogen, Germany 
Citrat acide –1- hydrate (C6H8O7 * H2O) Riedel-de Häen 
Concanavalin A from Canavalia ensiformis Sigma-Aldrich, Germany 
DMEM medium (low glucose) Gibco, UK 
N,N-Dimethylformamide (DMF) Sigma-Aldrich, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Fluka, Switzerland 
Ethanol 100% Fluka, Switzerland 
Fetal calf serum, South America (FCS) Greiner Bio-One, USA 
Formaldehyde ≥ 36.5% Riedl-de-Haën, Germany 
Gentamycine (50mg / ml in deionised water) Gibco, UK 
L-Glutamine  Gibco, UK 
Granulocyte-macrophage colony stimulating factor (GM-CSF) BD, USA 
Ionomycin Sigma-Aldrich, Germany 
Isofluran
®
Curamed vet inhalation anesthetic Essex Tierarznei, Germany 
Isopropanol Merck, Germany 
Isoton II (acid-free balanced electrolyte solution) Beckman Coulter, USA 
2-Mercaptoethanol (50 mM) Gibco, UK 
[methyl-
3
H] Thymidine solution Amersham, Germany 
Paraformaldehyde (PFA) Merck, Germany 
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Penicillin/Streptomycin (100 units/ml Penicillin G Sodium;  
50 µg/ml Streptomycin Sulfate in 85% Saline) 
Gibco, UK 
Phorbol 12- myristate 13-acetate (PMA) Sigma-Aldrich, Germany 
Potassium chloride (KCl)  Fluka, Switzerland 
Potassium hydrogen carbonate (KHCO3)  Merck, Germany 
Potassium dihydrogen phosphate (KH2PO4)  Carl-Roth, Germany 
RPMI 1640 medium (+L-glutamine) Gibco, UK 
Sodium acetate (CH3COONa) Merck, Germany 
Sodium carbonate (Na2CO3)  Carl-Roth, Germany 
Sodium chloride (NaCl)  Carl-Roth, Germany 
Sodium hydrogen carbonate (NaHCO3)  Merck, Germany 
Sodium dihydrogen phosphate (NaH2PO4) Merck, Germany 
di-Sodium hydrogen phosphate (Na2HPO4) Merck, Germany 
Sodium hydroxide (NaOH) Carl-Roth, Germany 
Streptavidin–horseradish peroxidase conjugate (ELISPOT) BD Pharmingen, USA 
[methyl-
3
H]Thymidine 5.0 Ci / mmol Amersham, Bioscience 
Trypan blue Sigma-Aldrich, Germany 
Tween 20  Carl-Roth, Germany 
 
4.3 Solutions and buffers 
Table 3: Solutions and buffers 
Solution/buffer: Composition: 
ABTS-solution 0.3 g/l ABTS in 0.1 M citric acid 
ABTS / H2O2 0.03% (v/v) H2O2 in ABTS-solution 
Acetate solution (0.1 M) 
148 ml acetic acid 0.2 mM to 352 ml of 0.2 mM sodium acetate; 
adjust volume to 1 l with water, pH 5.0 
ACK lysis buffer 0.1 mM EDTA; 1 mM KHCO3; 155 mM NH4Cl; pH 7.3 
Alsever’s solution 
2.05% Glucose, 0.8% sodium citrate, 0.42% sodium chloride, 0.055% 
citric acid/H2O (w/v) 
Blocking buffer (ELISpot) 2% BSA/PBS (w/v) 
Dilution buffer (ELISpot) 2% BSA/PBS (w/v) 
MACS buffer 0.5% BSA; 2 mM EDTA in PBS 
Permeabilization buffer 0.5% BSA; 0.5% Saponin/PBS (w/v) 
2% PFA 2% PFA/PBS (w/v), pH 7.0 (fixation) 
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PBS (phosphate-buffered 
saline) 
2.7 mM KCl; 1.8 mM KH2PO4; 137 mM NaCl; 10 mM Na2HPO4; pH 
7.4 
Trypan blue solution 0.1% Trypan blue/PBS (w/v) 
 
4.4 Antigens and adjuvants 
Table 4: Antigens and adjuvants 
Antigen / Adjuvant: Company: 
S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-
monomethoxy polyethylene glycol (BPPcysPEG) 
HZI, Germany 
Cholera toxin B subunit (CTB) Sigma-Aldrich, Germany 
CpG ODN 1826 MOLBIOL, Germany 
Curdlan Sigma-Aldrich, Germany 
Cyclic-di-adenosine-mono.phosphate (c-di-AMP) HZI, Germany 
Cyclic-di-guanosine-mono-phosphate(c-di-GMP) HZI, Germany 
α-galactosylceramide polyethylene glycol (αGCPEG) HZI, Germany 
H5N1 Virosomes Berna Biotech, Switzerland 
HA peptide AA110-120 from influenza virus PR8 HZI, Germany 
ISCOM Berna Biotech, Switzerland 
Lipopolysaccharide (LPS) Sigma-Aldrich Germany 
EndoGrade Ovalbumin Hyglos, Germany 
Ovalbumin, grade VII Sigma-Aldrich, Germany 
Ovalbumin peptide AA323-339  HZI, Germany 
Ovalbumin peptide AA323-339-FITC  HZI, Germany 
For some experiments Ovalbumin-peptide AA323-339 was synthesized with a seven 
AA “spacer” at the C-terminal end. The C-terminal end of the spacer has been 
labeled with FITC (Fig. 6).Mutated FITC labeled peptides were generated by 
exchanging AA335 or AA336, for sequences see Table 5. 
 
 
 
 
 
 
Table 5: Sequences of mutated OVA-peptides 
Name: AA exchange: Final sequence: 
335A 335N →335A ISQAVHAAHAEIAEAGR 
335Q 335N →335Q ISQAVHAAHAEIQEAGR 
336A 336E →335A ISQAVHAAHAEINAAGR 
336D 336E →335D ISQAVHAAHAEINDAGR 
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Fig. 6: Schematic structure of FITC labeled OVA-peptide AA323-339.  The OVA-peptide (light 
blue box) is linked by a seven AA long spacer (grey box) to a FITC molecule (yellow circle). 
 
4.5 Consumables 
Table 6: Consumables 
Product: Company: 
15 and 50 ml Cellstar®tubes Greiner bio –one, Germany 
Cell culture plates TPP, Switzerland 
Cell strainer 100 µm BD Bioscience, USA 
CombiTips 1-10ml Eppendorf, Germany 
Cell trics 50 µm filter Partec GmbH, Germany 
Counter cuvettes Beckman Coulter, Germany 
FACS tubes 1.2 ml MP Biomedicals, France 
FACS tubes 5ml BD Bioscience, USA 
Injection needle 1ml 30G x ½“ Omnican F B. Braun, Germany 
Multistepper Matrix Thermo Scientific, Germany 
Parafilm American National Can, USA 
Pasteur Pipettes  Brand GmbH + Co. KG, Germany 
Petri dishes Greiner Bio-one, Germany 
Pipette Tips Greiner Bio-one, Germany 
Serological Pipettes 5/10/25 ml Roth, Germany 
Safe lock reaction tubes Eppendorf, Germany 
Scissors and forceps B Braun, Germany 
Tissue culture flask 75/150 cm³ TPP, Switzerland 
VALO SPF eggs Lohmann Tierzucht GmbH, Germany 
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4.6 Cell culture media 
Table 7: Cell culture media 
Medium: Composition: 
RPMI complete 
RPMI 1640 supplemented with 10% heat inactivated FCS, 100 U/ml of 
penicillin, 50 μg/ml of streptomycin and 1 mM L-glutamine 
BMDC medium RPMI complete supplemented with 50 µg/ml gentamycine 
 
4.7 Instruments 
Table 8: Instruments 
Instrument: Company: 
Centrifuge Biofuge pico 
Heraeus, Germany Centrifuge Megafuge R40 
Centrifuge Multifuge 3S-r 
CTL Immunospot analyzer CTL-Europe GmbH, Germany 
Cell counter Z2 Beckman Coulter, Germany 
ELISA Reader Synergy2 BioTek Laboratories GmbH, Germany 
Flow Cytometer Aria2, Canto, LSRII  BD, USA 
Freezer and Fridge Liebherr, Germany 
Cell harvester ICH-110 INOTECH, Switzerland 
Handystep Brand, Germany 
Heating magnetic stirrer IKA Labortechnik, Germany 
Incubator Heraeus, Germany 
Micropipettor Hirschmann Laborgeräte, Germany 
pH-meter Hannah Instruments, Germany 
Pipettbay Thermo Scientific, Germany 
Precision 2000 automated microplate pipetting 
system 
BioTek laboratories, Germany 
Plate washer ELx 405 
Scale TE1502S 
PerkinElmer, Finland 
Scintillation Counter Wallac 1450 
Sterile hood Hera Safe Thermo Scientific, Germany 
Vortex Genie-2 Omnilab, Germany 
Water bath Köttermann, Germany 
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4.8 H5N1 Influenza virus 
The used influenza virus strain NIBRG-14 displays H5N1 and is a vaccine reference 
strain originally created by the National Institute for Biological Standards and Control 
(NIBSC) by using reverse genetics to combine A/Vietnam/1194/2004 (H5N1) virus (in 
which the polybasic HA cleavage site has been excised) and A/PR/8/34 (H1N1) 
virus. The used technique is described in detail for creation of a similar strain in [208]. 
The virus used for experiments was propagated and titrated as described in section 
5.5. 
 
4.9 Mice 
Six to eight weeks old female BALB/c and C57BL/6 mice were purchased from 
Harlan Winkelmann GmbH (Borchen,Germany). OTII, DO11.10, TCR-HA and 
C57BL/6 Thy1.1 mice were bred in-house at the HZI animal facility. OTIIxThy1.1 
mice were generated by crossing at the HZI. 
Jα281 knock out (KO) mice were kindly provided by the animal facilities of the Max 
Planck Institute for Infection Biology (Berlin). 
Mice were treated in accordance with local and European Community guidelines and 
kept under SPF conditions in individual ventilated cages with food and water ad 
libitum. Experiments using animals were done with the permission of the local 
authorities; permission numbers: 33.11.42502-04-104/07/2007 and 33.11.42502-04-
105/07/2007 from the local government (Bezirksregierung Braunschweig). 
 
 
Table 9: Phenotypes of used transgenic mouse strains 
Name: Background: Phenotype: Reference: 
DO11.10 BALB/c 
CD4
+
 T cells express only T cell receptors with affinity 
for OVA-peptide AA323-339 
[209] 
OTII C57BL/6 
CD4
+
 T cells express only T cell receptors with affinity 
for OVA-peptide AA323-339 
[210] 
TCR-HA BALB/c 
CD4
+
 T cells express only T cell receptors with affinity 
for HA-peptide AA110-120 from influenza strain PR8 
[211] 
Thy1.1 C57BL/6 
All T lymphocytes express CD90.1 in contrast to wild 
type mice that express CD90.2; e.g. congenic marker  
[212] 
Jα281 KO BALB/c 
By the KO of Jα281 gene, cells of these mice cannot 
express NKT cell receptor and thus lack functional 
NKT cells 
[213] 
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5 Methods 
5.1 Cell isolation 
In all experiments mice were sacrificed by CO2 inhalation or cervical dislocation.  
 
5.1.1 Spleen and lymph nodes 
Spleen and/or lymph nodes (LNs) were removed and minced with the piston of a 3 ml 
syringe through a 100 µm nylon mesh to obtain a single cell suspension. The 
erythrocytes were lysed by ACK buffer for 1-2 minutes, followed by a washing step. 
To remove dead cell clumps, the cell suspension was filtered again though a 100 µm 
nylon mesh. 
 
5.1.2 Bone marrow  
For generating bone marrow derived dendritic cells (BMDCs), hind legs were 
removed and cleaned from muscles and flesh. The intact bones were disinfected with 
ethanol for 1-2 min. In a clean bench, both ends of every bone were cut and the bone 
marrow was flushed out with medium by using a syringe. The bone marrow was 
disrupted with a syringe to obtain a single cell suspension. After lysis of erythrocytes 
with ACK buffer the cell number was adjusted to 1x106/ml by diluting the cells in full 
RPMI supplemented with Gentamycine. To differentiate the cells to DC like cells, 
GM-CSF (5 ng/ml) was added and cells were cultured in 6 well plates (5 ml/well) for 
5-6 days in the incubator. Beginning from day 3, 2 ml of medium per well were 
exchanged daily. After 5-6 days cells were fully differentiated and were used as DCs. 
 
5.2 Antibody staining for flow cytometry 
5.2.1 Surface antigens 
The staining of surface antigens was performed in PBS on ice. A pre-diluted mix of 
all antibodies plus a live/dead staining dye was added to the suspended cells, which 
were then vortexed. After 30 min at 4°C in the dark, staining was stopped with 4-10 
volumes of PBS. 
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5.2.2 Intracellular cytokine staining  
When intracellular cytokines were stained, Brefeldin A was used to block the cytokine 
transport from the endoplasmic reticulum (ER) to the Golgi apparatus. By this 
treatment cytokines accumulated in the ER were stained after permeabilization of the 
cell membrane. In brief, cells were fixated with 2% paraformaldehyde (PFA) in PBS 
for at least 30 min at 4°C. Then cells were permeabilized by 30 min incubation in 
permeabilization buffer (perm. buffer). After centrifugation and decanting the 
supernatant (SN), the Abs mixtures pre-diluted in perm. buffer were added. After 30 
min at 4°C in the dark, staining was stopped with 4-10 volumes of perm. buffer. For 
reducing the unspecific background, an additional washing step with perm. buffer 
flushed unbound Abs out of the cells. After washing cells one time with PBS they 
were ready for analysis. 
 
5.2.3 Cell labeling with carboxyfluorescein succinimidyl ester (CFSE)  
Cells were labeled with CFSE for quantification of proliferation and discrimination of 
undivided and divided cells by flow cytometry,. The labeling was performed with 
carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), which can easily pass 
cell membranes due to its acetate groups. Inside the cell, CFDA-SE is converted by 
esterases to CFSE and binds covalently to intracellular molecules [214]. While 
CFDA-SE has no fluorescent properties, CFSE can be excited with a blue laser and 
measured in the FITC channel. 
With every division of a cell, all molecules are equally distributed to the two daughter 
cells, halving the amount of CFSE molecules in the next generation. This reduction of 
fluorescent molecules is detected by a flow cytometer as a 50% loss of signal 
strength. When the CFSE signal of proliferated cells is displayed as a histogram, as 
shown in Fig. 7A, a typical pattern is seen - every peak from right to left represents 
one round of division, starting with undivided cells. With the FlowJo software it is 
possible to calculate the number of cell generations and to mark these in the 
histogram (Fig. 7B).  
 
 
Methods 
36 
 
 
Fig. 7: Histogram showing cell proliferation tracked by CFSE dilution. A: Peak pattern as detected directly 
by LSR2 B: Peak pattern with marked cell generations calculated by FlowJo software 
 
5.3 Flow cytometry 
5.3.1 Fluorescence Activated Cell Sorting (FACS) 
In most experiments pure and well-characterized cell populations sorted by FACS 
were used. When fluorochromes with overlapping spectral properties were used in 
the same staining, spectral overlap compensation was performed by using single 
stainings for every used antibody. 
 
5.3.1.1 Naïve non-activated CD4+ T cells 
For sorting of naïve non-activated CD4+ T cells, single cell suspensions from spleen 
and LNs were stained for CD4, CD25, CD62L and, in case of C57BL/6 background of 
the donor mice, also for CD44. The cells were sorted with a BD FACS Aria 2, 
according to the shown gating strategy (Fig. 8). The first gate (P1) selected total 
lymphocytes by forward scatter area (FSC-A) and side scatter area (SSC-A). Single 
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cells were discriminated from doublets with gate two (P2) and three (P3) by FSC-A 
against FSC-heights (FSC-H) and SSC-A against SSC-width (SSC-W), respectively. 
The next gating on cells positive for CD4 (CD4+; PE-Cy7) and expressing high levels 
of CD62L (CD62Lhi; FITC) selected the naïve CD4 population (P4). Cells negative for 
CD25 (CD25-; PE) and with low expression of CD44 (CD44lo; APC) were non-
activated as shown in the last gate (P5). In total the cells were sorted for CD4+CD25-
CD44loCD62Lhi with purity higher than 99%. 
 
 
Fig. 8: Gating strategy for sorting of naïve non-activated CD4
+
 T cells from OTII mice.Screen 
shots from FACS DIVA software which was used for cell sorting are shown. Cells are gated on leucocytes (gate 
P1) and subsequently on singlets by FSC (gate P2) and SSC (gate P3). Gating of CD62L
hi
 (FITC) and CD4
+
 (PE-
Cy7) (gate P4) selects naïve cells and by excluding CD25
+
 (PE) and CD44
hi
 (APC) (gate P5) non-activated cells 
are chosen. 
 
5.3.1.2 NKT cells 
For some experiments NKT cells were sorted from single cell suspensions of 
splenocytes. Cells were stained for CD8, CD11b, CD11c, B220 and DX5 with PE 
conjugated Abs and for NK1.1 with APC labeled Ab. The sorting gate was targeted 
on PE- APC+ cells to isolate NKT cells. 
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5.3.1.3 Dendritic cells 
DCs were sorted either from BMDC culture or for some experiments from 
splenocytes. The cells were stained and sorted for CD11c and MHC class II. The 
target population was CD11c+ and MHC class II intermediate/high. When sorting DCs 
from spleen it was necessary to sort the cells two times to achieve a purity >99%. 
 
5.3.2 Analysis of cells 
Cells were analyzed using either BD FACSCanto or BD LSR2. From every sample at 
least 1x104 cells from in vitro proliferation experiments and 1x106 cells from in vivo 
experiments were acquired. After spectral overlap compensation with the BD FACS 
Diva Software, FCS-files were exported and analyzed with FlowJo software from 
Tree Star. 
 
5.4 Determination of cell numbers 
To determine cell numbers in suspensions the electronic cell counter Z2 from 
Beckman Coulter was used. The cell suspensions were diluted 1:500 or 1:1000 in 
Isoton II. Using the Multisizer analyzer and Accucomb software, the cell population 
with a size between 5 µm and 16 µm of diameter was chosen and counted. 
Everything below 5 µm was debris and was not counted. 
 
5.5 Propagation and titration of H5N1 influenza virus 
Fertilized SPF hen eggs incubated for 10 days at 37°C at 50-70% humidity and 
regularly rotated. Virus stock was diluted in PBS with 1:10 serial dilutions from 10-2 to 
10-4. The eggs were candled and embryonated eggs at the same stage of 
development selected. For each virus dilution 5 eggs were infected by injection into 
the chorioallantoic cavity. The holes were sealed and eggs were incubated for 48 h 
and subsequently stored overnight at 4°C. Eggs were carefully opened and allantoic 
fluids were collected, pooled for each concentration and stored at 4°C. The virus titer 
was determined by hemagglutination test (HA-test). For this test 1:2 serial dilutions 
from allantoic fluids were performed in round bottom 96 well plates. To each well the 
same volume of standardized red blood cell (RBC) suspension was added and plates 
were gently vortexed. After 30-45 min at room temperature the highest dilution of 
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virus that caused complete hemagglutination was determined. The HA titer is the 
reciprocal of the dilution of virus in the last well with complete hemagglutination. 
 
5.6 In vitro proliferation assay 
5.6.1 Stimulation with antigen 
For the in vitro proliferation assays, sorted naïve non-activated CD4+ T cells from 
TRC transgenic mice were labeled with CFSE and co-cultured with BMDCs plus 
antigen for 4-5 days in the incubator. In some experiments, DCs sorted from spleens 
(sDCs) were used. For most experiments 1x105 T cells were co-cultured with 1x104 
BMDCs and in some experiments also with 1x104 NKT cells in round bottom 96-well 
plates. The used antigen dose ranged from 0.02-100,000 nM of OVA-peptide AA323-
339 or HA-peptide AA110-120. 
 
5.6.2 Stimulation with αCD3 and αCD28 antibodies 
For obtaining CD4+ T cells proliferation independent of antigens, αCD3 and αCD28 
antibodies were used. In about half of the experiments spleen cells depleted from 
CD8 cells by FACS were used (5x105 cells per well of a 96-well plate with flat 
bottom). For the other part of experiments, sorted naïve non-activated CD4+ T cells 
co-cultured with BMDCs were used, as described above (5.6.1). Since the used 
antibodies stimulate T cells directly by binding to the CD3 complex, activation of cells 
is independent from the Ag specificity of the TCR. With this method it is possible to 
stimulate cells from wild type animals (C57BL/6 and BALB/c) and from TCR 
transgenic mice (OTII and DO11.10). To measure the proliferation, CD8 depleted 
spleen cells or sorted CD4+ T cells were labeled with CFSE after sorting. The cells 
were cultured in the incubator for 4-5 days in the presence of 1 µg/ml αCD28 Ab and 
αCD3 Ab titrated in a range of 0.03-64 µg/ml. 
 
5.6.3 Culture conditions 
For the in vitro proliferation assays different culture conditions were used. Beside the 
“normal” conditions (only complete RPMI), for some experiments Th17 polarizing 
conditions were necessary. These “Th17 inducing conditions” were achieved by 
Methods 
40 
 
adding IL-6 (20 ng/ml) and TGFβ (1 ng/ml) to the cell culture. In some experiments 
neutralizing Abs against IL-2, IL-4 and IFNγ (all 10 µg/ml) were added to the culture. 
 
5.6.4 Restimulation and staining for flow cytometry 
After 4-5 days, plates from in vitro proliferation assays were centrifuged and the SN 
removed by a fast flip of the plate. To restimulate the cells, 100 µl of medium 
supplemented with ionomycin (1 µg/ml) and phorbol 12-myristate 13-acetate (PMA) 
(0.01 µg/ml) were added per well and cells were incubated for 4 h. For the last 2 h of 
the incubation 100 µl medium supplemented with ionomycin, PMA and brefeldin A. 
The brefeldin A was double concentrated so that the final concentration in each well 
was 5 µg/ml. After restimulation, cells were stained for viability and CD4 and fixated 
with PFA. Intracellular staining for IL-4, IL-17 and IFNγ was performed after 
permeabilization. 
 
5.7 Adoptive transfer 
For analyzing the T helper polarization in vivo, sorted naïve CD4+ T cells from 
OTIIxThy1.1 double transgenic animals were adoptively transferred to normal 
C57BL/6 mice. Since the transferred T cells express Thy1.1 (CD90.1) and all T cells 
from normal C57BL/6 express Thy1.2 (CD90.2), the two cell populations can be 
distinguished by flow cytometry by staining for this marker. Recipient mice received 
2x106 CFSE labeled cells by tail vein injection and were immunized the following day 
with 0.4-625 µg OVA plus 25 µg LPS, either by intraperitoneal injection (i.p.) or by 
intra food pad injection (i.fp.). After 3-5 days the mice were sacrificed and spleens 
were taken. From mice, immunized i.p. before, additionally a peritoneum lavage (2 x 
3 ml PBS) was performed, whereas from animals immunized i.fp. the draining 
popliteal LNs were isolated. The isolated cells were restimulated with ionomycin + 
PMA and brefeldin A was added, as above described (5.6.4). 
After staining for CD3, CD4, CD90.1 and viability, cells were fixated with 2% PFA. 
For staining intracellular cytokines, cells were permeabilized and fluorochrome 
labeled Abs against IL-4, IL-17 and IFNγ were added, as described in 5.2.2. Read out 
was performed by flow cytometry. 
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5.8 Immunizations 
5.8.1 Immunization strategy 
5.8.1.1 Ovalbumin titrations 
Groups of 3 or 5 six to eight weeks old C57BL/6 mice were immunized by either i.p. 
or s.c. route on day 0, 14 and 21 of the experiment. The animals were given different 
dosages of OVA ranging from 0.2 to 625 µg plus 20 or 25 µg LPS per mouse. Control 
groups received PBS, 20 or 25 µg LPS, or 25 µg OVA alone. 
On day 42 mice were sacrificed and sampled. 
 
5.8.1.2 H5N1 virosome titrations 
For the combined immunization and challenge study, 6 groups of 15-16 six to eight 
weeks old BALB/c mice were immunized by i.n. route on day 0, 14 and 21 of the 
experiment. Each animal received 2.5 µg of c-di-AMP co-administered with 0.1, 0.5, 
2.5 or 7.5 µg H5N1 virosomes diluted in 20 µl Ampuwa by application of 10 µl of 
solution to each nostril while anesthetized by isofluran inhalation. Control group mice 
received Ampuwa or 7.5 µg H5N1 virosomes alone. On day 42 five mice of each 
group were sacrificed and sampled. The remaining 10-11 mice per group were 
challenged with H5N1 virus, as described in section 5.8.2. 
 
5.8.1.3 Immunizations including αGCPEG 
Groups of 5 six to eight weeks old C57BL/6 or Jα281 knock out (KO) mice were 
immunized by i.n. route with 50 µg OVA co-administered with either 5 µg αGCPEG, 
10 µg LPS, 1 µg BPPcysPEG, 10 µg CTB, 200 µg Curdlan, 20 µg CpG, 7.5 µg 
ISCOM or 2.5 µg c-di-GMP. Control animals received PBS or OVA alone. In most 
experiments animals were immunized on day 0, 14, 21 and sacrificed on day 42, 
whereas in experiments with Jα281 KO mice the animals were only immunized on 
day 0 and 14 and sacrificed on day 35. 
 
5.8.2 H5N1 challenge of immunized mice 
Mice immunized with H5N1 virosomes as described in section 5.8.1.2 were 
challenged with 5x105 focus forming units of H5N1 virus in 50 µl of PBS by i.n. route 
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on day 49. For the next 6 days the animal weight was determined in the morning and 
animal health conditions were monitored in the morning and in the evening. Mice 
which lost 25% or more of starting bodyweight or were in bad physiological 
conditions were sacrificed and considered as killed by the infection. After 6 days all 
remaining animals were sacrificed. 
 
5.8.3 Sampling of mice 
The immunized animals were anesthetized with isofluran inhalation and 500 µl of 
blood were taken with glass capillaries from the retro-orbital plexus. Animals were 
sacrificed by CO2 inhalation afterwards and spleens were isolated and processed as 
described in 5.1.1. To obtain serum the blood samples were incubated for 1 h at 
37°C to coagulate, followed by incubation for 30 min at 4°C to enable the retraction of 
coagula. For separating serum from cellular blood components, tubes were 
centrifuged for 10 min at 7000 rpm. SNs were transferred to new tubes and stored at 
-20°C. 
 
5.8.4 Enzyme linked immunospot assay (ELISpot) 
For characterization of antigen specific cytokine producing spleen cells of immunized 
mice ELISpot assays were performed. The day before sampling, 96 well pates with 
hydrophobic high protein binding Immobilin-P-Membranes on the flat bottom were 
coated with capture antibodies against IL-4, IL-17 or IFNγ diluted in PBS overnight at 
4°C. The next day, plates were washed and incubated for 2 h at RT with complete 
medium to block unspecific binding sites on the membrane with protein from the 
medium. For every sample, 11 wells with 5x105 spleen cells per well were used. The 
first 5 wells were restimulated with 5 µg/ml of OVA or 2 µg/ml of H5N1 virosomes, 
whereas the next 5 wells were left unstimulated to determine unspecific cytokine 
production (background). The last well was stimulated with 5 µg/ml of concanavalin A 
(Con A) as positive control. Unused wells on each plate were filled with medium 
alone as negative controls. The plates were incubated at 37°C and 5% CO2 for 24 
(IFNγ) or 48 h (IL-4 and IL-17). To stop cytokine production, plates were washed with 
deionized water followed by washing with buffer (0.05 % Tween-20 in PBS). To 
detect captured cytokines on the membranes, corresponding biotinylated detection 
antibody diluted in buffer (10% FCS/PBS) was added and incubated for 2 h at room 
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temperature (RT). After washing with wash buffer, horseradish peroxidase (HRP) 
coupled to avidin was added and incubated for another hour at RT. The plates were 
then washed with wash buffer and subsequently with PBS. To visualize the captured 
cytokines, substrate solution was added and within the next 5 to 30 min red/brownish 
spots appeared by the HRP catalyzed reaction. The reaction was stopped by 
washing the plate with deionized water. Plates were dried overnight at RT in the dark 
and then scanned with the ImmunoSpot series 3A analyzer. The spots were counted 
by using the ImmunoSpot image analyzer software (version 3.2; Cellular Technology, 
Ltd.). Every spot in this assay represents one cell producing the captured cytokine. 
For every sample spot forming units (SPU) per 1x106 spleen cells subtracted by the 
background from unstimulated cells were calculated. The results are presented as 
mean values +/- the standard error of the mean (SEM) and the subtracted 
background levels are given for each experiment. All antibodies for ELISpot were 
used according to the manufacturer’s protocols supplied in the kits. 
 
5.8.5 Proliferation assays based on 3H-thymidine incorporation 
Antigen specific proliferation of cells from immunized mice can be determined by 
measuring the incorporation of radioactive 3H-thymidine into the DNA after antigen 
restimulation. Spleen cells from all animals per group were pooled and 5x105 cells 
per well were seeded in 96 well plates. To restimulate the cells, either OVA was 
added to final concentrations of 10, 20, 30 and 40 μg/ml or H5N1 virosomes with final 
concentrations of 0.1, 1 and 2 µg/ml. As a positive control ConA was used at a final 
concentration of 5 μg/ml, whereas negative controls were cultured in medium alone. 
For all conditions quadruplicates were cultured in the incubator for 96 h. For the last 
16-18 h, 1 μCi/well of 3H-thymidine was added to the plates. Then, cells were 
harvested on filter mats with the cell harvester ICH-110 and dried in a microwave for 
30 s. Melt-on scintillator sheets were melted on the filter forming a wax layer which 
acts as a solid scintillation material. The concentration of 3H-thymidine was 
determined by measuring the radioactivity in counts per minute (cpm) using the γ-
scintillation counter 1450 MicroBeta. Results were presented as mean values +/- the 
SEM. 
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5.8.6 Identification of T helper and polyfunctional CD4+ T cells by flow 
cytometry 
For 3 mice per group 2x107 spleen cells per animal were cultured with either 2 µg/ml 
of H5N1 virosomes for restimulation or medium alone as control for 20-24 h. For the 
last 4 h, 5 µg/ml brefeldin A was added to every sample. Cells were stained for 
viability, CD3, CD4 and CD8. After fixation, cells were permeabilized and stained for 
IL-2, IL-4, IL-17, IFNγ and TNFα. At least 1x106 cells per sample, viable at the time 
point of staining, were acquired by LSRII. 
 
5.9 Statistics 
Statistical analyses were performed with the GraphPad Prism 5 software. For 
multiple group comparisons, one-way ANOVA or two-way ANOVA were applied. For 
comparisons of independent groups, Student’s t test or the Mann-Whitney test were 
performed. For comparisons of matched groups, paired Student’s t test or Wilcoxon 
matched test were performed. In figures, n.s. indicates not significant; *** indicates p 
< 0.001; ** indicates p < 0.01; and * indicates p < 0.05. 
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6 Results 
6.1 Influence of antigen dose on T helper polarization 
6.1.1 Setup of the in vitro proliferation assay 
To study the polarization of naïve CD4+ T cells into different Th phenotypes a reliable 
and simple model had to be established. An in vitro proliferation assay with sorted 
naïve CD4+ T cells from TCR transgenic mice and the corresponding Ag presented 
by sorted BMDCs fulfills these criteria. The workflow for this assay, as well as the 
following data acquisition and analysis are shown schematically in Fig. 9 and 
explained in detail in section 5.6. In a first set of experiments, Ag concentrations were 
defined, ranging from those not inducing proliferation at all to those triggering 
induction of full proliferative T cell responses. 
 
 
Fig. 9: Schematic workflow for the established in vitro proliferation assay. Sorted naïve CD4
+
 T cells from 
DO11.10 or OTII mice were labeled with CFSE and co-cultured with sorted BMDCs in the presence of different Ag 
concentrations for 5 days. After restimulation with ionomycin and PMA cells were stained with fluorescent labeled 
Abs and acquired with a LSRII. Analysis of samples was performed using FlowJo and subsequently GraphPad 
software. 
 
 
Results 
46 
 
The strongest proliferation rates of OTII and DO11.10 CD4+ T cells are normally 
achieved using OVA-peptide AA323-339 at concentrations around 500-1000 nM 
(0.89-1.78 µg/ml) [215]. The Ag dose for the presented experiments was limited to a 
concentration of 100000 nM due to the pH buffering capacity of the cell culture 
medium. Higher Ag concentrations resulted in a color change of medium, indicating 
acidic conditions which are not favorable for cell culture experiments. Thus, the Ag 
concentration of 100000 nM was used as starting point for a 1:3 serial dilution down 
to 1.7 nM. To measure the Ag dose dependent proliferative capacity of CD4+ T cells, 
FACS sorted naïve CD4+ T cells from OTII mice were labeled with CFSE and 
stimulated with different Ag concentrations in the presence of BMDCs. It was 
observed that T cell proliferation started at an Ag concentration between 5 to 15 nM, 
reaching the peak of proliferative capacity (84%) between 412 and 1235nM and 
persisted at this level for higher Ag doses (Fig. 10). Therefore the range of Ag 
concentrations from 100000 nM down to 1.7 nM (or 0.2 nM in some experiments) 
fulfills the before defined criteria and was used in the following experiments. The 
same Ag titration experiments performed with DO11.10 cells displayed comparable 
results (data not shown). Cells that were not stimulated with Ag served as controls 
and did not show any proliferation. In the subsequently performed in vitro proliferation 
assays divided CD4+ T cells (as identified by CFSE dilution) that were viable at the 
time point of staining (identified by fixable live/dead stain) were analyzed for cytokine 
production. 
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Fig. 10: Proliferation of OTII cells stimulated with different Ag concentrations. Histograms display the CFSE 
signal from OTII cells, which were co-cultured with BMDCs in the presence of the indicated OVA-peptide AA323-
339 concentrations for five days. With every cell division, the CFSE signal strength is approximately halved. The 
shown percentages indicate the ratio of proliferated live CD4
+
 T cells. 
 
6.1.2 In vitro proliferation assay with OVA-peptide 
6.1.2.1 Comparison of DO11.10 and OTII cells 
Differences in Ag induced Th1/Th2 immune response are described when comparing 
C57BL/6 and BALB/c mice [62]. To investigate whether the animal background 
influences the conducted experiments and in particular Th17 polarization in vitro, the 
proliferation assays were performed in parallel with cells obtained from DO11.10 
(BALB/c background) and OTII (C57BL/6 background) mice. In both transgenic 
mouse strains the TCRs expressed on CD4+ T cells recognize the OVA-peptide 
AA323-339. To mimic the natural setting of Ag uptake and presentation to T cells, 
sorted BMDCs from BALB/c or C57BL/6 mice were pulsed for 3 h with different OVA-
peptide concentrations and subsequently washed with medium. Ag pulsed DCs were 
co-cultured with sorted CFSE-labeled naïve CD4+ T cells isolated from DO11.10 or 
OTII mice at a 1 to 10 ratio for 5 days. After restimulation with ionomycin and PMA, 
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cells were analyzed by FACS for IL-4 (Th2), IL-17 (Th17) and IFNγ (Th1) production 
(Fig. 11). DO11.10 cells showed an induction of Th2 and Th17 cells at low Ag doses 
(5-46 nM), whereas Th1 polarization was detected at slightly higher peptide 
concentrations (15-137 nM). Th1 phenotype represented the dominant T cell subset 
independently of the used Ag concentration. A complete different picture was 
observed in the differentiation of OTII cells. Here, IL-4 and IFNγ were produced at 
medium to high Ag concentrations (416-1235 nM) whereas Th17 polarization was 
detected at very high peptide doses (33333 and 100000 nM). Comparing cells 
derived from both strains, a higher number of IL-4 and IL-17 producing CD4+ T cells 
were detected when cells from OTII mice were used, whereas polarization to IFNγ 
production was observed in higher frequencies when using cells from DO11.10 mice. 
Not only differences in Th induction were observed, but also in relation with 
dependence of Th17 polarization on the Ag dose. CD4+ T cells sorted from DO11.10 
mice differentiated to IL-17 producing cells in the presence of low peptide 
concentrations, whereas OTII cells were only polarized towards the Th17 phenotype 
when stimulated with high Ag doses. This observation pointed to a general difference 
between the used mouse strains and was further investigated in subsequently 
performed experiments. 
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Fig. 11: Cytokine profiles of DO11.10 and OTII cells from in vitro proliferation assays with OVA-peptide. 
BMDCs were loaded for 3 h with Ag before co-cultured with naïve CD4
+
 T cells for 5 days. Shown is the 
expression of the Th characteristic cytokines IL-4, IL-17 and IFNγ by viable, divided CD4
+
 T cells. Each bar 
represents the mean of three samples plus SEM. n.p.= no proliferation 
 
In the above described experimental setting strongly fluctuating numbers of BMDCs 
per well were observed, suggesting an influence on the outcome of the assays. The 
washing process after the loading of DCs with Ag was identified as one reason for 
fluctuating cell numbers. Thus, the setup was slightly changed to guarantee constant 
and comparable conditions. For the following experiments the Ag was kept in culture 
for the whole incubation time of 5 days. The subsequently obtained results revealed 
T cell proliferation already at 0.6 nM, two dilution steps lower as compared to the 
previous experimental conditions (Fig. 4). The pattern of Th1 and Th2 polarization 
was quite similar between DO11.10 and OTII cells, and showed induction at low to 
medium peptide concentrations. Strikingly, there was a 5-fold and 2-fold increase of 
IL-4 and of IFNγ positive OTII cells, respectively, as compared to the previous 
experimental conditions. This increase was not observed when DO11.10 cells were 
used. The main differences were observed at the level of polarization of Th17 cells. 
The distribution of IL-17 producing OTII cells was comparable to the first method, 
whereas the DO11.10 cells showed a complete different behavior. Two peaks were 
observed for Th17 induction, the first one at the lowest Ag concentrations and the 
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second one at highest Ag concentrations. Remarkable was the detected increase of 
IL-17 positive OTII cells from about 8% to more than 21% in the presence of high 
peptide concentrations. Due to the modification of the experimental setup, not only 
constant starting cell numbers per well were obtained, but also a more homogeneous 
induction pattern of Th1 and Th2 cells for the two mouse strains. The previously 
observed differences in Th17 polarization were preserved. Thus, for all further in vitro 
proliferation assays, the Ag was kept in the culture for the whole incubation time. 
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Fig. 12: Cytokine profiles of DO11.10 and OTII cells from in vitro proliferation assays with OVA-peptide. 
The Ag was present in the cultures during the whole of 5 days. Shown is the expression of the Th characteristic 
cytokines IL-4, IL-17 and IFNγ by viable and divided CD4
+
 T cells. Each bar represents the mean of three 
samples plus SEM. n.p.= no proliferation. 
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6.1.2.2 Th17 inducing conditions 
Beside stimulation strength, the cytokine milieu is a major factor in Th differentiation. 
The effect of Th polarizing cytokines can also be Ag dose dependent. The cytokines 
IL-6 and TGFβ were described to induce Th17 polarization [65]. Therefore, it was 
investigated whether IL-6 and TGFβ influence Ag dose dependent Th17 
differentiation in in vitro proliferation assays. The culture of cells in complete RPMI 
medium without any additional supplements is called “normal condition” and was 
compared to “Th 17 inducing conditions”, which were achieved by the addition of IL-6 
and TGFβ to the cell cultures. The normal condition was included in all experiments 
as internal control, since fluctuations in the percentage of cytokine expressing cells 
were observed between different experiments, whereas the pattern of Th induction at 
different Ag doses was quite constant. 
 
In the set of experiments performed with DO11.10 cells the results for IL-4 and IFNγ 
under normal conditions were comparable to the previous presented results (Fig. 13). 
However, a difference in Th17 polarization was detected under normal conditions, 
since the previously observed low dose peak for IL-17 was absent. Addition of IL-6 
and TGFβ completely blocked the induction of Th2 cells and clearly reduced the Th1 
polarization at all tested peptide concentrations. Regarding IL-17, the low dose peak 
as well as the high dose peak were detected under Th17 inducing conditions, and the 
overall percentage of Th17 cells was increased at all Ag concentrations. 
 
The same set of experiments was performed with sorted naïve CD4+ T cells derived 
from OTII mice (Fig. 14). Under normal conditions Th1 and Th2 cells were induced at 
low to medium Ag doses, whereas cells were polarized towards the Th17 phenotype 
at the highest peptide concentrations. The presence of polarizing cytokines in the 
culture led to almost complete blockage of Th1 and Th2 polarization, and the 
percentage of IL-17 producing cells was strongly increased. Especially at high 
peptide doses high numbers of IL-17 producing cells were observed (i.e. 
approximately every second cell differentiated to the Th17 phenotype). 
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Fig. 13: Cytokine profiles of DO11.10 cells from in vitro proliferation assays with OVA-peptide. Naïve CD4
+
 
T cells sorted from DO11.10 mice were cultured under normal and Th17 inducing (IL-6 + TGFβ) conditions. 
Shown is the expression of the Th characteristic cytokines IL-4, IL-17 and IFNγ by viable and divided CD4
+
 T cells 
after 5 days in culture. Each bar represents the mean of three samples plus SEM. n.p.= no proliferation. 
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Fig. 14: Cytokine profiles of OTII cells from in vitro proliferation assays with OVA-peptide. Naïve CD4
+
 T 
cells sorted from OTII mice were cultured under normal and Th17 inducing (IL-6 + TGFβ) conditions. Shown is the 
expression of the Th characteristic cytokines IL-4, IL-17 and IFNγ by viable and divided CD4
+
 T cells after 5 days 
in culture. Each bar represents the mean of three samples plus SEM. n.p.= no proliferation. 
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6.1.2.3 Neutralization of blocking cytokines 
Published studies demonstrated that the Th polarization is not only affected by IL-6 
and TGFβ but also by IL-2, IFNγ and IL-4 (see sections 2.1.3 and 2.1.4). To study the 
effect of these three cytokines on Th polarization in combination with different Ag 
doses, neutralizing Abs against IL-2 (αIL-2), IL-4 (αIL-4) and IFNγ (αIFNγ) were 
added to the cultures, either alone or in combinations. The experiments were 
performed in parallel with cells sorted from DO11.10 and OTII mice. 
 
The addition of αIL-2 to DO11.10 cells led to a reduction of IL-4 producing cells, as 
compared to standard conditions (Fig. 15). In contrast, neutralizing Abs against IFNγ 
led to increased Th2 polarization at very low peptide concentrations. However, this 
increase was not observed when αIFNγ was added in combination with αIL-4 or αIL-2 
and αIL-4. Instead, these combinations led to a reduced percentage of IL-4 positive 
cells. In assays with OTII cells, Th2 induction was observed at high peptide 
concentrations (Fig. 16). The neutralization of secreted IL-2, either alone or in 
combination with αIL-4 and αIFNγ, completely blocked Th2 polarization. As compared 
to DO11.10 cells, only a small increase in Th2 cell frequencies was detected when 
IFNγ was neutralized. 
 
 
 
Results 
54 
 
normal conditions
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0.0
2.5
5.0
7.5
10.0
addition of IL-2
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0.0
2.5
5.0
7.5
10.0
addition of IL-4
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0.0
2.5
5.0
7.5
10.0
addition of IFNg
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0.0
2.5
5.0
7.5
10.0
addition of IL-4 and IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0.0
2.5
5.0
7.5
10.0
addition of IL-2, IL-4 and IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0.0
2.5
5.0
7.5
10.0
IL
-4
+
 d
iv
id
e
d
 C
D
4
+
 c
e
ll
s
 [
%
]
Conc. of OVA-peptide (AA323-339) [nM]
 
Fig. 15: IL-4 production of DO11.10 cells in the presence of different neutralizing Abs. Shown is the 
expression of the Th2 characteristic cytokine IL-4 by viable and divided CD4
+
 T cells stimulated with OVA-peptide 
under standard culture conditions or in the presence of blocking Abs against IL-2, IL-4 and IFNγ alone or in 
combinations. Each bar represents the mean of three samples plus SEM. 
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Fig. 16: IL-4 production of OTII cells in the presence of different neutralizing Abs. Shown is the expression 
of the Th2 characteristic cytokine IL-4 by viable and divided CD4
+
 T cells stimulated with OVA-peptide under 
standard culture conditions or in the presence of blocking Abs against IL-2, IL-4 and IFNγ alone or in 
combinations. Each bar represents the mean of three samples plus SEM. 
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The polarization towards the Th17 phenotype in DO11.10 was positively influenced 
by the addition of neutralizing Abs, especially in the presence of αIFNγ (Fig. 17).The 
combinations of two or all three Abs led to a huge increase of IL-17 producing cells. 
The strongest increase was observed at high peptide concentrations. Due to this 
dose dependent increase of Th17 polarization, the peak of IL-17 producing cells 
which was observed under normal conditions at low doses, was less characteristic 
under neutralizing conditions. Also in the experiments performed with OTII cells, the 
addition of neutralizing Abs influenced Th17 induction (Fig. 18). As in all previous 
presented experiments with OTII cells, Th17 polarization was exclusively detected at 
high Ag doses. In the experiments with neutralizing Abs, only the addition of αIL-2 
alone or in combination with αIL-4 and αIFNγ led to an almost 3-fold increase of IL-17 
producing cells in the presence of high peptide concentrations. 
  
Th1 cells were detected in DO11.10 mice at relatively low Ag concentrations (Fig. 
19). The addition of αIL-2, the combination of αIL-4 and αIFNγ and especially the 
addition of all three Abs blocked the induction of IFNγ producing cells. In experiments 
performed with OTII cells a Th1 induction was observed at medium Ag doses (Fig. 
20). The combined neutralization of IL-4 and IFNγ led to a 50% decrease of IFNγ 
producing cells. However, the strongest effect was observed by adding αIL-2 or the 
combination of all three neutralizing Abs. Under these conditions OTII cells were 
hardly polarized towards the Th1 phenotype. 
Results 
56 
 
normal conditions
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
addition of IL-2
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
addition of IL-4
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
addition of IFNg
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
addition of IL-4 and IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
addition of IL-2, IL-4 and IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
IL
-1
7
+
 d
iv
id
e
d
 C
D
4
+
 c
e
ll
s
 [
%
]
Conc. of OVA-peptide (AA323-339) [nM]
 
Fig. 17: IL-17 production of DO11.10 cells in the presence of different neutralizing Abs. Shown is the 
expression of the Th17 characteristic cytokine IL-17 by viable and divided CD4
+
 T cells stimulated with OVA-
peptide under standard culture conditions or in the presence of blocking Abs against IL-2, IL-4 and IFNγ alone or 
in combinations. Each bar represents the mean of three samples plus SEM. 
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Fig. 18: IL-17 production of OTII cells in the presence of different neutralizing Abs. Shown is the expression 
of the Th17 characteristic cytokine IL-17 by viable and divided CD4
+
 T cells stimulated with OVA-peptide under 
standard culture conditions or in the presence of blocking Abs against IL-2, IL-4 and IFNγ alone or in 
combinations. Each bar represents the mean of three samples plus SEM. 
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Fig. 19: IFNγ production of DO11.10 cells in the presence of different neutralizing Abs. Shown is the 
expression of the Th1 characteristic cytokine IFNγ by viable and divided CD4
+
 T cells stimulated with OVA-
peptide under standard culture conditions or in the presence of blocking Abs against IL-2, IL-4 and IFNγ alone or 
in combinations. Each bar represents the mean of three samples plus SEM. 
normal conditions
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
20
25
30
addition of IL-2
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
20
25
30
addition of IL-4
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
20
25
30
addition of IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
20
25
30
addition of IL-4 and IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
20
25
30
addition of IL-2, IL-4 and IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
5
10
15
20
25
30
IF
N
+
 d
iv
id
e
d
 C
D
4
+
 c
e
ll
s
 [
%
]
Conc. of OVA-peptide (AA323-339) [nM]
 
Fig. 20: IFNγ production of OTII cells in the presence of different neutralizing Abs. Shown is the expression 
of the Th1 characteristic cytokine IFNγ by viable and divided CD4
+
 T cells stimulated with OVA-peptide under 
standard culture conditions or in the presence of blocking Abs against IL-2, IL-4 and IFNγ alone or in 
combinations. Each bar represents the mean of three samples plus SEM. 
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In conclusion, for both mouse strains the strongest effects on Th polarization were 
observed when all three neutralizing Abs were added together to the in vitro 
proliferation assays. The induction of Th17 cells was strongly increased, whereas 
Th1 and Th2 subsets were almost absent in the presence of the combined 
neutralizing Abs. 
 
6.1.2.4 Combination of Th17 inducing conditions and neutralization Abs 
The previous results raised a new question, namely, whether Th17 induction follows 
the same Ag dose dependent pattern under highly polarizing conditions as observed 
before. Thus, in the following experiments cells obtained from DO11.10 and OTII 
mice were cultured under conditions in which combinations of all three neutralizing 
Abs together with Th17 polarizing cytokines were evaluated. 
 
In assays performed with DO11.10 cells under normal conditions, an induction of IL-4 
producing cells was observed at the lowest Ag dose and at high Ag dose (Fig. 21). 
Highest numbers of IL-17 producing cells were detected at the quite low peptide 
concentration of 15 nM, whereas the induction of Th1 cells was observed at medium 
Ag dosages. The combination of Th17 culture conditions and the addition of 
neutralizing Abs almost completely blocked Th1 and Th2 differentiation and only few 
IL-4 producing cells were present in samples with the lowest Ag concentrations. The 
detection of Th17 cells was considerably increased at Ag doses of 416 nM and 
higher, resulting in more than 40% of Th17 cells at the two highest peptide 
concentrations. However, this increase was not observed at low Ag doses. In fact, 
the low dose peak of Th17 cells, which was observed in the previous experiments 
with DO11.10 mice under Th17 inducing conditions or addition of neutralizing Abs 
alone, was absent.  
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Fig. 21: Cytokine profiles of DO11.10 cells under Th17 polarizing conditions in the presence of 
neutralizing Abs. Shown are the Th cytokine profiles of viable and divided CD4
+
 DO11.10 cells from in vitro 
proliferation assays with different OVA-peptide doses. Cells were either cultured under normal conditions or under 
Th17 inducing conditions in the presence of neutralizing Abs against IL-2, IL-4 and IFNγ. Each bar represents the 
mean of three samples plus SEM. n.p.= no proliferation. 
 
Proliferation assays with OTII cells were performed under the same conditions as for 
DO11.10 cells. Under normal conditions, the differentiation towards Th2 cells was 
very weak with less than 0.5% of CD4+ T cells producing IL-4 (Fig. 22). IL-17 
producing cells were instead detected in high numbers with rising Ag dose, with a 
clear trend of Th17 induction at highest Ag doses. High numbers of Th1 cells were 
present in the samples stimulated with medium peptide concentrations (i.e. around 
137 nM). Surprisingly, addition of neutralizing Abs under Th17 inducing conditions 
resulted in an increase of Th2 polarization at the lowest Ag doses. In this context, it 
has to be stated that the general level of IL-4 producing cells was quite low as 
compared to previous experiments. As expected, these culture conditions boosted 
polarization of IL-17 producing cells starting from 416 nM OVA-peptide, where a 
maximum of 60% Th17 polarization was reached. In contrast, Th1 cells were almost 
absent under these culture conditions. 
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To conclude, in both TCR transgenic mouse strains the combination of Th17 inducing 
conditions and neutralizing Abs led to further increased Th17 polarization, especially 
at high Ag concentrations. Under these highly Th17 polarizing conditions, the low 
dose peak of IL-17 producing cells was not detected in DO11.10 cultures. 
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Fig. 22: Cytokine profiles of OTII cells under Th17 polarizing conditions in the presence of neutralizing 
Abs. Shown are the Th cytokine profiles of viable and divided CD4
+
 OTII cells from in vitro proliferation assays 
with different OVA-peptide doses. Cells were either cultured under normal conditions or under Th17 inducing 
conditions in the presence of neutralizing Abs against IL-2, IL-4 and IFNγ. Each bar represents the mean of three 
samples plus SEM. n.p.= no proliferation. 
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6.1.2.5 Neutralization of IFNβ 
Published studies demonstrated that also type 1 IFNs can influence Th differentiation 
(see sections 2.1.3 and 2.1.4). Application of IFNβ is a common treatment of MS in 
humans [216], and was reported to reduce IL-17 levels in the EAE mouse model 
[217]. Thus, the effect of IFNβ on antigen dose dependent Th polarization was 
investigated by the addition of neutralizing Ab to the established in vitro proliferation 
assays with TCR transgenic CD4+ T cells. The experiments were carried out with 
DO11.10 cells under normal and Th17 inducing conditions. 
 
The highest numbers of Th2 cells were detected under normal culture conditions at 
peptide concentrations around 5 nM and the abundance of the IL-4 producing cells 
was halved by IFNβ neutralization in the cultures (Fig. 23). Th17 inducing culture 
conditions resulted in an almost complete blockage of the Th2 phenotype, regardless 
of the addition of αIFNβ Ab.  
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Fig. 23: IL-4 production of DO11.10 cells in the presence of αIFNβ under normal and Th17 inducing 
conditions. Shown is the expression of the Th2 characteristic cytokine IL-4 by viable and divided CD4
+
 T cells 
stimulated with OVA-peptide under standard or Th17 inducing culture conditions or in the presence of blocking 
Abs against IFNβ. Each bar represents the mean of three samples plus SEM. n.p.= no proliferation. 
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IL-17 producing cells were induced under normal conditions at high and very high 
peptide concentrations. Neutralization of IFNβ resulted in no significant changes with 
respect to the polarization towards Th17 phenotype (Fig. 24). Worth to mention is the 
lack of the low dose Th17 peak in this experiment performed under normal 
conditions. The addition of IL-6 and TGFβ increased the induction of IL-17 producing 
cells at very low, high and especially at very high peptide concentrations. Under 
these Th17 inducing conditions, the low dose Th17 peak was restored. However, 
also under these experimental conditions the addition of neutralizing Abs did not 
result in any significant effect.  
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Fig. 24: IL-17 production of DO11.10 cells in the presence of αIFNβ under normal and Th17 inducing 
conditions. Shown is the expression of the Th17 characteristic cytokine IL-17 by viable and divided CD4
+
 T cells 
stimulated with OVA-peptide under standard or Th17 inducing culture conditions or in the presence of blocking 
Abs against IFNβ. Each bar represents the mean of three samples plus SEM. n.p.= no proliferation. 
 
The induction of Th1 cells was highest at lower Ag doses around 5 nM (Fig. 25). As 
observed in the previous experiments, Th17 inducing conditions blocked Th1 
polarization. In this experiment the abundance of IFNγ producing cells was reduced 
by the factor 5. Addition of αIFNβ Ab did not influence Th1 polarization, neither under 
normal nor under Th17 polarizing culture conditions.  
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Another way to visualize the results from this experiment is presented in Fig. 26. 
Here, instead of displaying the percentages of the viable and divided CD4+ T cells 
that produce Th cytokines, the fraction of Th subsets for each Ag concentration was 
calculated. This representation of the data clearly demonstrated the dominance of 
Th17 cells at high and very high peptide concentrations under all performed culture 
conditions. As shown before, the increased induction of IL-17 producing cells at low 
Ag doses also resulted in a regime shift of Th subsets (see the two lower panels of 
Fig. 26).  
 
no Ab addition
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
10
20
30
n.p.
addition of IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
10
20
30
n.p.
no Ab addition
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
10
20
30
n.p.
addition of IFN
0.
2
0.
6
1.
7 5 15 46 13
7
41
2
12
35
37
04
11
11
1
33
33
3
10
00
00
0
10
20
30
n.p.
IF
N
+
 d
iv
id
e
d
 C
D
4
+
 c
e
ll
s
 [
%
]
Conc. of OVA-peptide (AA323-339) [nM]
normal conditions
Th17 inducing conditions
 
Fig. 25: IFNγ production of DO11.10 cells in the presence of αIFNβ under normal and Th17 inducing 
conditions. Shown is the expression of the Th1 characteristic cytokine IFNγ by viable and divided CD4
+
 T cells 
stimulated with OVA-peptide under standard or Th17 inducing culture conditions or in the presence of blocking 
Abs against IFNβ. Each bar represents the mean of three samples plus SEM. n.p.= no proliferation. 
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Fig. 26: Fractions of Th subsets under normal or Th17 inducing conditions in the presence of αIFNβ. For 
each peptide concentration the fractions of Th subsets from mean values of measured Th cytokine producing 
cells were calculated. Mean values were calculated from three samples. n.p.= no proliferation. 
 
Taken together, the obtained results demonstrated that neutralization of IFNβ did not 
result in changes of Th polarization at all tested Ag concentrations and culture 
conditions, as observed by consistent production of IL-4, IL-17 and IFNγ by CD4+ T 
cells. 
 
6.1.2.6 Influence of DC to T cell ratio 
The strength of stimulation is not only determined by the concentration of Ag, but 
also the number of DCs in the assay could have an effect on Th polarization. This 
effect is explained by differences in the available number of MHC class II molecules 
loaded with the Ag, as well as the degree of co-stimulation to T cells. Thus, the 
influence of the ratio between DCs and T cells on Ag dose dependent Th polarization 
was investigated by adding different amounts of sorted BMDCs to the in vitro 
proliferation assays. In all the experiments presented before the ratio between DCs 
and TCs was 1 to 10. Addition of less DCs per well resulted in a dramatic reduction 
of the proliferation rates. Especially at low peptide concentrations, the T cells neither 
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proliferated nor differentiated towards Th cells. An enhanced DC number led to 
slightly increased T cell proliferation and Th cytokine secretion. In the following 
experiments with OTII cells, the amount of DCs was increased by the factor 2 or 4 
and compared to the standard ratio of 1 to 10 under both normal and Th17 inducing 
conditions. 
 
The number of Th2 cells under normal conditions was very high as compared to 
previous experiments and a peak at 137 nM of OVA-peptide at the 1 to 10 ratio (Fig. 
27). With increasing numbers of DCs in the culture, the polarization to Th2 phenotype 
was further increased, and the induction peak shifted to lower Ag concentrations. 
Th17 inducing conditions blocked the appearance of IL-4 producing cells almost 
completely at all DC to T cell ratios. Th17 polarization was induced at highest Ag 
concentrations under normal conditions (Fig. 28). The addition of more DCs to the 
culture clearly increased the percentage of IL-17 producing cells and shifted the start 
of Th17 induction to lower peptide concentrations. Under Th17 inducing conditions 
the percentage of Th17 cells multiplied by 4 at the 1 to 10 ratio and the induction 
started already at medium Ag doses and reached a maximum at higher Ag doses. 
The increase of DCs under these conditions did not change the Th17 profile. IFNγ 
producing cells were detected especially at medium doses around 46 nM under 
normal conditions (Fig. 29). In contrast to Th2 and Th17 cells, the dose dependent 
peak of Th1 cells was not shifted by the increased frequency of DCs in the culture. 
However, the percentage of Th1 cells was decreased when more DCs were present. 
As expected, the addition of Th17 polarizing cytokines blocked the induction of IFNγ 
producing cells. The different DC to T cell ratios did not influence this effect. 
 
To summarize, the addition of higher DCs numbers to the cultures increased Th2 and 
Th17 induction under normal culture conditions but not when Th17 polarizing 
cytokines were present. 
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Fig. 27: IL-4 production of OTII cells cultured with DCs at different ratios. Shown is the expression of the 
Th2 characteristic cytokine IL-4 by viable and divided CD4
+
 T cells stimulated with OVA-peptide under standard or 
Th17 inducing culture conditions at DC to T cell ratios of 1 to 10, 1 to 5 or 1 to 2.5. Each bar represents the mean 
of three samples plus SEM. n.p.= no proliferation. 
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Fig. 28: IL-17 production of OTII cells cultured with DCs at different ratios. Shown is the expression of the 
Th17 characteristic cytokine IL-17 by viable and divided CD4
+
 T cells stimulated with OVA-peptide under standard 
or Th17 inducing culture conditions at DC to T cell ratios of 1 to 10, 1 to 5 or 1 to 2.5. Each bar represents the 
mean of three samples plus SEM. n.p.= no proliferation. 
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Fig. 29: IFNγ production of OTII cells cultured with DCs at different ratios. Shown is the expression of the 
Th1 characteristic cytokine IFNγ by viable and divided CD4
+
 T cells stimulated with OVA-peptide under standard 
or Th17 inducing culture conditions at DC to T cell ratios of 1 to 10, 1 to 5 or 1 to 2.5. Each bar represents the 
mean of three samples plus SEM. n.p.= no proliferation. 
 
6.1.3 In vitro proliferation assay with HA-peptide 
In the majority of the presented experiments a difference between DO11.10 and OTII 
mice in the Ag dose dependent Th17 induction was observed. DO11.10 cells 
displayed Th17 polarization either at very low Ag doses or at very low and very high 
doses, whereas cells from OTII mice were polarized towards Th17 phenotype only in 
the presence of high and very high Ag doses. They never differentiated in significant 
numbers to IL-17 producing cells at very low or low peptide concentrations. The 
following experiments were performed to reveal the reason for this unexpected 
difference between the two mouse strains. As a first step the Ag dose dependent 
induction of Th cells was investigated in a third strain, to compare if the results 
resemble either DO11.10 or OTII animals. For this experiment the TCR-HA 
transgenic mouse strain on BALB/c background featuring CD4+ T cells specific for 
the HA-peptide AA110-120 from influenza virus PR8 was chosen. To assure similar 
conditions as in the proliferation assays presented before, the same sorting 
parameters, culture conditions and peptide concentrations were used. Th2 induction 
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was observed at low and medium Ag doses and the addition of Th17 polarizing 
cytokines resulted in decreased IL-4 producing cells (Fig. 30). Polarization towards 
Th17 cells was detected at very low and low peptide concentrations. A 3-fold 
increase was observed under Th17 inducing conditions at these Ag doses. Th1 cells 
were present in all samples at comparable amounts (between 6 and 9%), with the 
highest values at 100000 nM of the Ag. Th17 polarizing conditions again reduced the 
induction of IFNγ producing cells at all Ag doses, especially at high concentrations. 
 
In summary, the cytokine profiles were more similar to those from DO11.10 cells than 
to those of OTII cells. The effect of Th17 inducing conditions on IL-17 producing cells 
in TCR-HA transgenic mice was also more comparable with the results obtained 
using DO11.10 cells. Interestingly, the blocking effect of Th17 polarizing cytokines on 
Th1 and Th2 cells was less efficient in TCR-HA cells than in DO11.10 and OTII cells. 
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Fig. 30: Cytokine profiles of TCR-HA cells under normal and Th17 polarizing conditions Shown are the Th 
cytokine profiles of viable and divided CD4
+
 TCR-HA cells from in vitro proliferation assays with different HA-
peptide doses. Cells were either cultured under normal conditions or under Th17 inducing conditions. Each bar 
represents the mean of three samples plus SEM. n.p.= no proliferation. 
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6.1.4 Studies with FITC-labeled OVA-peptides 
One possible explanation for the observed differences in Ag dose dependent Th17 
polarization is related to differences in the MHC class II haplotype on DCs obtained 
from BALB/c mice expressing MHC H2d or C57BL/6 mice expressing MHC H2b. In 
fact, the two MHC haplotypes could differ in their affinity to the used peptides, leading 
to differences in the loading of MHC class II molecules. This can in turn result in 
different numbers and densities of presented epitopes on DCs, thereby influencing 
the Ag concentration made available for T cells and subsequently leading to different 
Th polarizations. To measure the amount of presented OVA-peptide on DCs from 
either BALB/c or C57BL/6 mice, the peptide was labeled with a fluorochrome. To this 
end, the OVA-peptide AA323-339 was synthesized with a so-called “spacer”, a 
sequence of seven amino acids at the N-terminus that sticks out of the MHC class II 
binding grove for peptides. The Serine in the spacer was synthesized as D-isomer to 
prevent cleavage by proteases. To the N-terminus of the spacer a molecule of the 
fluorescent organic compound fluorescein (FITC) was linked. For more detailed 
information and the complete structure see section 4.4. To check if the modification 
of the peptide is affecting the biological activity, the induction of proliferation in 
DO11.10 and OTII cells was compared to the unlabeled peptide. For the in vitro 
proliferation assay a peptide concentration inducing maximal T cell proliferation was 
used (500 nM). Both peptides induced comparable proliferation in DO11.10 and OTII 
cells, thereby proving that the labeling did not influence the biological activity of the 
peptide (Fig. 31). 
 
To investigate whether the binding affinity to the OVA-peptide is different, peptide 
loading experiments with BMDCs derived from BALB/c and C57BL/6 mice were 
performed. For each peptide concentration, 5x105 sorted BMDCs from each mouse 
strains were loaded for 3 h and subsequently washed 3 times to remove the peptide 
that had not been taken up from the samples. 
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Fig. 31: Biological activity of FITC-labeled OVA-peptide. The FITC-labeled OVA-peptide AA323-339 was 
compared to the unlabeled peptide at a concentration of 500 nM. The proliferation of sorted DO11.10 and OTII 
naïve CD4
+
 T cells was accessed by measuring the dilution of the CFSE signal. Cells were gated on viability and 
CD4
+
. Each panel shows the percentage of proliferated cells in a representative out of three independent 
samples. 
 
The obtained results revealed a high percentage of FITC positive CD11c+ MHCII+ 
cells for peptide concentrations starting from 412 nM up to maximal Ag dose in both 
cell types (Fig. 32). At lower peptide concentrations differences in the percentage of 
loaded DCs were observed in two independent experiments. In the presented 
experiment peptide loaded DCs derived from C57BL/6 mice (MHC H2b) were 
detected in higher frequencies than peptide loaded DCs derived from BALB/c mice 
(MHC H2d). In the second experiment a higher percentage of loading at low Ag doses 
was observed in DCs derived from BALB/c mice (data not shown). A possible reason 
for the observed differences might be the limited number of samples. Due to the 
huge amount of needed DCs, only one sample per Ag concentration for each mouse 
strain was prepared. However, in another experiment with less Ag doses but three 
replicates per condition no differences between the DCs of the two mouse strains 
were observed at low peptide concentrations (see left panel of Fig. 33). This 
suggests that the affinities MHC H2d and MHC H2b molecules to OVA-peptide 
AA323-339 do not differ. These results rule out that differences in affinity could be 
responsible for the observed differences in Th17 polarization between DO11.10 and 
OTII cells. 
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Fig. 32: Loading of FITC-labeled OVA-peptide on BMDCs from BALB/c and C57BL/6 mice. The left panel 
shows the percentage of CD11c+ MHCII+ cells positive for the FITC-labeled peptide. The right panel shows the 
median fluorescent intensity (MFI) of FITC from loaded DCs. 
 
6.1.5 Studies with mutated OVA-peptides 
In parallel to the previously described experiments with FITC-labeled OVA-peptide 
AA323-339, peptides with a changed amino acid sequence were synthesized and 
also labeled with FITC linked to a spacer. The mutated peptides were used to 
investigate the possibility that differences in TCR affinity to the Ag might be 
responsible for the observed variations in Th17 polarization. All CD4+ T cells within 
one TCR transgenic mouse strain display exactly the same TCR with invariant affinity 
to the specific peptide. Thus, differences in TCRs in DO11.10 and OTII animals may 
influence the affinity to the OVA-peptide AA323-339. X-ray crystallography 
experiments revealed the anchor positions of MHC class II and TCR binding to the 
OVA-peptide AA323-339 [215]. These amino acids are crucial for the peptide binding 
and an exchange against different amino acids prevents proliferation of DO11.10 and 
OTII cells. In a study by Sette et al. [218] every single amino acid of OVA-peptide 
AA323-339 was exchanged one by one with alanine and the resulting proliferation of 
DO11.10 and OTII cells was measured. The exchange at position 335 led to 
decreased proliferation of DO11.10 cells, whereas OTII cells kept the same 
proliferation pattern. The opposite effect was observed when exchanging amino acid 
336 with alanine. These two mutated OVA-peptides, called in the following “335A” 
and “336A”, were used for further experiments in this work. Since the structural effect 
resulting from exchanging asparagine in position 335 or glutamic acid in position 336 
with alanine is quite drastic, two additional mutated peptides were generated in which 
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less severe structural changes were expected. Namely, the peptide “335Q”, in which 
asparagine was exchanged with glutamine, and the peptide “336D”, where glutamic 
acid was exchanged with aspartic acid, were designed. 
 
The loading efficiency of these altered peptides at different concentrations on 
BMDCs derived from BALB/c and C57BL/6 mice was then analyzed. No significant 
differences in the loading with any of the used peptides were observed independently 
of the mouse strain (Fig. 33). However, a trend of less efficient loading of BALB/c 
cells with “335Q” and “336A” was detected. As compared to the normal wild type 
peptide, especially peptides “335A” and “336D” were loaded less frequently to the 
DCs at low and medium concentrations. 
 
In vitro proliferation assays with the mutated peptides revealed their strongly 
impaired biological activities. AA335 mutated peptides showed a 1000 fold 
decreased capacity to induce proliferation of DO11.10 cells, whereas AA336 altered 
peptides completely failed to induce robust proliferation of OTII cells at all tested 
concentrations (data not shown). Due to the impaired proliferation a Th differentiation 
was also not achieved, and it was thus not analyzed. 
 
The performed experiments did not answer the question if differences in TCR affinity 
to the OVA-peptide are responsible for the observed differences in Th polarization. 
However, these results highlighted the importance of TCR affinity, since the influence 
of altered peptide sequences on T cell proliferation was clearly demonstrated.  
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Fig. 33: Loading of FITC-labeled sequence mutated OVA-peptides on BMDCs. The percentage of CD11c+ 
MHCII+ cells from BALB/c or C57BL/6 mice positive for the indicated FITC-labeled peptide is shown. Each bar 
represents the mean of three samples plus SEM. 
 
6.1.6 In vitro proliferation assay with αCD3 antibody 
Another approach to study Th polarization is the stimulation of T cells with αCD3 and 
αCD28 Abs, which is independent of the TCR affinity to the Ag. The αCD3 Ab binds 
to the CD3 molecules of the TCR complex and triggers the activation signal cascade. 
The secondary signal necessary for full T cell activation is provided by αCD28 Ab 
binding to CD28 on the T cell. Since this method is not dependent on the specificity 
of TCR to Ag, it is possible to stimulate T cells from wild type mice and thus to study 
stimulation strength dependent Th polarization. To provide the necessary cell to cell 
contact to the T cells in this system, BMDCs were added to the cultures at a ratio of 1 
to 10. Analogous to the peptide based stimulation described before, the αCD3 Ab 
concentration inducing T cell proliferation had to be defined. Proliferation started at a 
αCD3 Ab concentration of 0.06 µg/ml, and reached a maximum at 1-2 µg/ml (data 
not shown). For the following in vitro proliferation assays 1:2 serial dilutions of αCD3 
Ab were performed, ranging from 0.06 to 32 µg/ml. The highest proliferation rates 
were achieved by the addition of 2 µg/ml of αCD28 Ab and were then applied 
throughout all experiments.  
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Sorted naïve CD4+ T cells from BALB/c mice were polarized towards a Th2 
phenotype at medium and especially at high αCD3 Ab concentrations under normal 
culture conditions (Fig. 34). Th17 inducing conditions almost completely blocked the 
induction of IL-4 producing cells. IL-17 producing cells were induced at the lowest Ab 
concentrations and the overall percentage of IL-17 positive cells was increased under 
Th17 polarizing conditions. For Th1 cells no real polarization peak was observed, 
IFNγ producing cells were present in all samples with comparable abundances. Also 
under Th17 inducing conditions Th1 cells were detected in all samples, but only in 
50% decreased levels as compared to the normal culture conditions. The induced 
Th17 pattern resembles the Ag dose dependent Th17 polarization observed in cells 
obtained from TCR-HA mice. 
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Fig. 34: Cytokine profiles of BALB/c cells under normal and Th17 polarizing conditions following Ag-
independent stimulation The Th cytokine profiles of viable and divided CD4
+
 BALB/c cells from in vitro 
proliferation assays with different αCD3 Ab concentrations are shown. Cells were either cultured under normal 
conditions or under Th17 inducing conditions in the presence of 2 µg/ml αCD28 Ab. Each bar represents the 
mean of three samples plus SEM. 
 
Cells from C57BL/6 mice differentiated into a Th2 phenotype at very low and very 
high stimulus under normal culture conditions (Fig. 35). Th17 inducing conditions 
blocked the Th2 induction and only at the highest αCD3 Ab concentrations IL-4 
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producing cells above 0.5% were detected. As already observed for proliferation 
assays with BALB/c cells, the induction of Th17 cells occurred at low αCD3 Ab doses 
and was strongly increased under Th17 inducing conditions. IFNγ producing cells 
were induced at high concentrations and, surprisingly, this induction was increased 
under Th17 polarizing conditions. Similar to the results obtained with BALB/c cells, 
the induced Th17 pattern resembles the Ag dose dependent Th17 polarization of 
TCR-HA cells. 
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Fig. 35: Cytokine profiles of C57BL/6 cells under normal and Th17 polarizing conditions following Ag-
independent stimulation The Th cytokine profiles of viable and divided CD4
+
 C57BL/6 cells from in vitro 
proliferation assays with different αCD3 Ab concentrations are shown. Cells were either cultured under normal 
conditions or under Th17 inducing conditions in the presence of 2 µg/ml αCD28 Ab. Each bar represents the 
mean of three samples plus SEM. 
 
As a next step, Ag-independent Th polarization of cells obtained from TCR 
transgenic and wild type animals was compared. To this end, sorted naïve CD4+ T 
cells from OTII animals were stimulated with αCD3 and αCD28 in the presence of 
C57BL/6 BMDCs. Only weak polarization towards Th2 phenotype was observed 
under normal culture conditions with two maximums at lowest and at high dose of 
αCD3 Ab (Fig. 36). Th17 cells were detected especially at low doses but the 
percentage of Th cells was quite low as compared to in vitro proliferation assays 
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performed with OVA-peptide. The induction of Th1 cells was observed at high 
stimulus concentrations. An unexpected result was the strong increase of Th1 and 
Th2 induction under Th17 polarizing conditions. Th1 cells peaked at very high Ab 
doses, whereas Th2 cells had a maximum at 4 µg/ml of αCD3 Ab. Also the 
polarization to IL-17 producing cells was increased. At a concentration of 0.06 µg/ml 
of αCD3 Ab, the percentage of Th17 cells raised from 1% to 15%.  
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Fig. 36: Cytokine profiles of OTII cells under normal and Th17 polarizing conditions following Ag-
independent stimulation The Th cytokine profiles of viable and divided CD4
+
 OTII cells from in vitro proliferation 
assays with different αCD3 Ab concentrations are shown. Cells were either cultured under normal conditions or 
under Th17 inducing conditions in the presence of 2 µg/ml αCD28 Ab. Each bar represents the mean of three 
samples plus SEM. 
 
These experiments clearly demonstrated an induction of Th17 cells by low strength 
stimulation in wild type mice as well as in TCR transgenic OTII animals. Thus, it can 
be hypothethized that the observed absence of Th17 polarization when OTII cells 
were stimulated with low doses of the OVA-peptide AA323-339 can be explained, at 
least in part, by differences in TCR affinity. 
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6.1.7 Adoptive transfer of TCR transgenic T cells to wild type recipient mice 
For studying Ag dose dependent Th polarization of OTII cells in a more natural 
setting, adoptive transfer experiments were performed. To identify the transferred 
TCR transgenic cells in the wild type C57BL/6 host, Thy1.1xOTII mice were used as 
donors. Thy1.1 (or CD90.1) is a so-called congenic marker. Wild type mouse strains 
express the “normal” Thy1.2 molecule, which differs slightly from Thy1.1 in structure 
but not in function. Non cross-reactive monoclonal Abs against each form of Thy1 are 
available and can be used to distinguish transferred from host cells. Naïve CD4+ T 
cells from Thy1.1xOTII double transgenic animals were sorted by FACS and labeled 
with CFSE. Cells were injected in the tail vein of each C57BL/6 recipient mouse. The 
next day, mice were immunized with 25µg OVA and 100µg Curdlan intra footpad. 
The draining lymph node of the foot pad is the popliteal lymph node (pLN) which is 
located at the hollow of the knee. To define the ideal time point after injection to 
measure proliferation and Th differentiation of transferred cells, three different time 
points were tested (1, 2 and 3 days post immunization). The pLNs from animals 
collected on day two and three were clearly larger than the pLNs from negative 
control mice and mice analyzed 1 day post immunization. Single cell suspensions 
from pLNs and spleens were stained with FACS Abs for viability, CD4, Thy1.1, IL-4, 
IL-17 and IFNγ. 
 
The recovered fractions of transferred cells in the host animals were quite constant 
between day 1 and 2 post immunization in pLNs and spleen (Fig. 37). A huge 
increase of transferred cells was observed in pLNs as well as in the spleens after 3 
days. The proliferation of transferred cells was measured by CFSE dilution and is 
shown as histograms in Fig. 37. After one day no divided cells were found in pLNs or 
spleen. Proliferation started at day 2 in the draining LNs and one day later almost all 
transferred cells detected in pLNs and spleen were activated and divided. To 
determine the induced Th phenotype of the divided cells, their cytokine profiles were 
analyzed. Cells from pLNs on day 2 did not produce cytokines (data not shown) and 
on day 3 cytokines were only detected in the cells isolated from pLNs (Fig. 38). 
Mainly Th17 and Th2 cells were induced by immunization, whereas IFNγ positive 
cells were almost not detectable. 
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Fig. 37: Time kinetics of T cell proliferation after adoptive transfer. The dot plots show the population of 
adoptively transferred Thy1.1xOTII cells in pLNs or spleen at indicated time points after intra footpad 
immunization with 25 µg OVA and 100 µg Curdlan. Histograms show the proliferation of transferred cells, as 
measured by CFSE dilution. Data for each day are from one mouse representative for the group. 
 
 
Fig. 38: Cytokine profiles of adoptively transferred cells. Shown is the production of IL-4, IL-17 and IFNγ by 
adoptively transferred Thy1.1xOTII cells isolated from pLNs or spleen 3 days post intra footpad immunization with 
25 µg OVA and 100 µg Curdlan. 
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Following these results, nine groups of three C57BL/6 mice were immunized for 3 
days with different concentrations of OVA co-administered with Curdlan by intra 
footpad injection after adoptive transfer of CFSE-labeled naïve CD4+ Thy1.1xOTII 
cells. Negative control animals received PBS. To compare the groups, the 
percentage of transferred cells isolated from recipient pLNs were analyzed and 
investigated with respect to their proliferative capacity (Fig. 39). In the PBS group, 
the adjuvant control group, and the two groups with either lowest or highest Ag dose 
in combination with Curdlan only small populations (<0.3%) of transferred cells were 
detected. In the OVA control group and all intermediate Ag dose groups comparable 
populations of transferred cells were observed. However, between the single animals 
in some cases big differences in the percentage of transferred cells were observed; 
especially in the 1 µg OVA and Curdlan group. The proliferation rates of transferred 
cells rose with the applied Ag dose and reached a maximum beginning with 25 µg of 
OVA (almost 100%). An influence of the adjuvant on proliferation was not observed, 
since also the cells of the control group immunized with OVA alone showed full 
proliferation.  
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Fig. 39: Characterization of adoptively transferred Thy1.1xOTII cells. The left panel shows the percentage of 
Thy1.1
+
 CD4
+
 T cells in pLNs from animals which were immunized with different doses of OVA + Curdlan after 
adoptive transfer of 2.5 x 10
6 
naïve CD4
+
 Thy1.1xOTII cells 4 days before. Right panel shows the proliferation of 
these cells measured by CFSE dilution. Every animal of each group (n = 3) was analyzed separately and the 
mean plus SD is shown.  
 
Th cytokine profiles of proliferated transferred cells were analyzed utilizing the 
established cytokine FACS panel. In the PBS and Curdlan control group no cytokine 
producing cells were detected, whereas some positive cells for each cytokine were 
found in the OVA control group (Fig. 40). IL-4 production was observed at all Ag 
concentrations in equal frequencies (around 0.5%). Only in the group immunized with 
Results 
80 
 
5 µg OVA and Curdlan higher percentages of IL-4 producing cells were found. The 
strongest polarization toward Th17 was detected in mice immunized with the lowest 
Ag dose. Immunization with 25 µg and 125 µg OVA resulted in the induction of 
intermediate Th17 responses, whereas 5 µg OVA resulted in low frequencies of IL-17 
producing cells. The complete opposite picture was observed when looking on Th1 
cells. A clear increase of IFNγ producing cells was detected in groups immunized 
with the two highest OVA doses, as compared to lower Ag doses. 
 
However, the analysis of cytokine profiles showed strong variations between animals, 
leading to high standard deviations. This explains that the observed differences in IL-
17 production were not statistically significant, despite the fact that the observed 
trend suggests a stronger Th17 polarization at the lowest Ag dose. This trend would 
contradict the observations from in vitro experiments using OVA-peptide for 
stimulation of OTII cells. However, it would be in agreement with the Ag-independent 
stimulation of OTII cells by αCD3 Ab, which led to Th17 induction when low Ab 
concentrations were used. Further, it is possible that in vivo and in vitro conditions 
result in different polarization behavior of TCR transgenic cells. 
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Fig. 40: Cytokine profiles of adoptively transferred Thy1.1xOTII cells. Production of IL-4, IL-17 and IFNγ by 
viable and divided adoptively transferred CD4
+
 Thy1.1xOTII cells, isolated from pLNs 3 days post intra footpad 
immunization with different doses of OVA and 100 µg Curdlan is shown. Every animal of each group was 
analyzed separately and the mean plus SD is shown. 
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6.1.8 Immunization studies with different dosages of OVA-protein  
The presented in vitro studies together with the in vivo passive transfer experiments 
strongly suggested that under natural conditions a Th17 immune response is elicited 
by low Ag doses. To validate these observations, the influence of Ag dose on Th 
polarization in vivo was evaluated (Fig. 41). Groups of three or five C57BL/6 animals 
were immunized by either i.p. or s.c. route with different dosages of OVA-protein and 
20 or 25 µg of LPS on day 0 and boosted on day 14 and day 21. At day 42 
splenocytes were analyzed with respect to cytokine secreting cells and proliferative 
capacity by ELISpot and 3H-thymidin incorporation assays. In parallel to the titration 
of the OVA-protein, also a titration of LPS at constant OVA concentration of 25 µg 
per animal was performed in the i.p. immunization. A dose of 25 µg of OVA per 
animal are routinely used to induce a robust immune response against the Ag and 
will be regarded as “standard dose” in the following. 
 
 
Fig. 41: Schematic illustration of the immunization strategy. Mice were immunized either by i.p or s.c. route 
with varying doses of OVA+LPS. The animals were boosted with the same OVA+LPS combination on day 14 and 
21. After a total of 42 days, mice were sacrificed and spleens were isolated for read out of the immune response, 
which was measured by performing ELISpot analysis and 
3
H-Thymidin proliferation assays. 
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As expected, in the groups immunized with PBS or LPS alone, only few IL-17 
secreting cells were detected after restimulation with OVA (Fig. 42). The lowest Ag 
dose only resulted in a weak Th17 immune response, whereas the immunization with 
1 µg of OVA led to significantly increased IL-17 responses as compared to the 
standard dose or even higher Ag concentrations. Titration of the co-administered 
LPS dose revealed a decreased number of Th17 cells when lowering the LPS 
dosage under 25 µg per animal. An increase of the LPS dose instead resulted in a 
significant higher number of IL-17 producing cells, as compared to standard 
immunization conditions. The groups immunized with OVA and LPS displayed an 
increased Ag specific proliferation, as compared to the negative control groups (Fig. 
43). Only the combination of 125 µg OVA and 25 µg LPS resulted in low levels of 
thymidine incorporation. 
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Fig. 42: IL-17 response of splenocytes after i.p. immunization with OVA+LPS. C57BL/6 mice were 
immunized three times with varying doses OVA+LPS by i.p. route. Spleens were pooled and IL-17 ELISpot 
assays were performed on OVA restimulated cells. Each bar represents the mean of five wells plus SEM; 
background was subtracted. **:p<0.01; ***:p<0.001; as compared to LPS alone or between groups as indicated. 
n=3 
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Fig. 43: Proliferation of splenocytes after i.p. immunization with OVA+LPS. C57BL/6 mice were immunized 
three times with varying doses OVA+LPS i.p.. Spleens were pooled and a 
3
H-Thymidin incorporation assay was 
performed on OVA restimulated cells. Each bar represents the mean of four wells plus SEM. **:p<0.01; compared 
to LPS alone. n=3 
 
To investigate if the observed induction of Th17 cells at low Ag concentrations was 
dependent on the route of immunization, an experiment with application of OVA and 
LPS by the s.c. route was performed. An IL-17 ELISpot performed with pooled 
splenocytes from the immunized mice revealed a significant increase of Th17 cells at 
the lowest Ag dose, as compared to the standard dose of 25 µg (Fig. 44). 
Immunization with higher Ag concentrations resulted in decreased Th17 induction. In 
PBS and LPS control groups no induction of IL-17 producing cells was detected. To 
evaluate the induction of Ag specific proliferation of immune cells by the 
immunization, a 3H-Thymidin incorporation assay was also performed. As expected, 
in cells from the two negative control groups very weak proliferation was observed as 
compared to groups immunized with Ag and LPS (Fig. 45). High Ag doses resulted in 
quite poor induction of specific immune cells, whereas the proliferation rate at the two 
lowest doses was modest, as compared to other groups. Strong proliferation was 
measured at the intermediate Ag concentrations of 5 and 25 µg per animal. The 
differences in optimal dosage for Th17 cells induction can be attributed to the fact 
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that s.c. vaccination is more efficient, since a higher number of APCs is locally 
available. 
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Fig. 44: IL-17 response of splenocytes after s.c. immunization with OVA+LPS. C57BL/6 mice were 
immunized three times with varying doses OVA+LPS by s.c. route. Spleens were pooled and IL-17 ELISpot assay 
was performed on OVA restimulated cells. Each bar represents the mean of five wells plus SEM; background was 
subtracted. *:p<0.05; ***:p<0.001; compared to LPS alone or between groups as indicated. n=5 
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Fig. 45: Proliferation of splenocytes after s.c. immunization with OVA+LPS. C57BL/6 mice were immunized 
3 times with varying doses OVA+LPS by s.c. route. Spleens were pooled and 
3
H-Thymidin incorporation assay 
was performed on OVA restimulated cells. Each bar represents the mean of 4 wells plus SEM. *:p<0.05; 
**:p<0.01; ***:p<0.001; compared to LPS alone. n=5 
 
Taking the proliferation and ELISpot data under account, a specific Th17 response 
was observed at low Ag concentrations, regardless of the route of application. These 
results gave further evidence that Th17 immune responses are normally elicited 
under conditions of weak Ag stimulation, as already observed in vitro when 
stimulating CD4+ T cells with αCD3 Ab.  
 
6.2 Effect on Th polarization and protective efficacy against the 
influenza virus resulting from vaccination using different Ag doses 
The above presented immunization studies with the model Ag OVA revealed that 
Th17 induction can be promoted in mice at low protein concentrations. Next, it was 
investigated if in vivo Th17 polarization at low antigen dosages is a general 
phenomenon or only related to certain Ags like OVA. It was decided to use a vaccine 
relevant Ag, which would also allow to address the potential impact of Th17 
polarization in overall protective efficacy conferred by the vaccine. To this end, mice 
were immunized with different concentrations of virosomes generated using Ags from 
Results 
86 
 
the avian influenza virus H5N1. These virosomes are small phospholipid bilayer 
particles, which present HA5 and NA1 molecules on their surface. They resemble the 
influenza virus and can enter host cells via HA mediated phagocytosis. As a 
consequence, immune responses against HA and NA are elicited. However, since 
virosomes contain no genetic material, they cannot replicate (see also 2.3). 
 
BALB/c mice were immunized on day 0, 14 and 21 by i.n. route with different 
dosages of H5N1 virosomes co-administered with c-di-AMP as adjuvant. Parts of the 
animals were analyzed 42 days after priming with respect to their Ag specific immune 
responses in terms of proliferation and the induced Th phenotypes. The remaining 
mice were challenged by i.n. application of a lethal dose of H5N1 virus (strain 
NIBRG-14) and their survival was monitored for the following 6 days. 
 
Immunization with 0.5, 2.5 and 7.5 µg (HA equivalents) of H5N1 virosomes plus c-di-
AMP led to strong Ag specific proliferation of spleen cells, as compared to the 
negative control groups and the group which received the lowest Ag concentration 
(Fig. 46). Strongest proliferation was observed in the group immunized with 2.5 µg 
virosomes plus adjuvant when cells were restimulated with 2 µg/ml of virosomes. 
With cells from the groups receiving 0.5 and 7.5 µg, the strongest proliferation was 
detected when cells were restimulated with 0.1 and 1 µg of Ag, respectively. These 
results demonstrate that already 0.5 µg of H5N1 virosomes in combination with c-di-
AMP are able to elicit a robust Ag specific cell pool after immunization. 
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Fig. 46: Proliferation of splenocytes after i.n. immunization with H5N1 virosomes and c-di-AMP. BALB/c 
mice were immunized three times with different dosages of H5N1 virosomes + c-di-AMP by i.n. route. Spleens 
were pooled and a 
3
H-Thymidin incorporation assay was performed after in vitro restimulation with indicated Ag 
doses. Each point represents the mean of four wells plus SEM. ***: p < 0.001; compared to H5N1 alone. n=5 
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To investigate Th immune responses, cytokine secretion by splenocytes was 
assessed by ELISpot assay. Between samples from mice immunized with 0.5, 2.5 or 
7.5 µg virosomes plus c-di-AMP no significant differences were observed (Fig. 47). 
They all showed high numbers of IL-17 and IFNγ producing cells and only few cells 
positive for IL-4. In the 2.5 µg plus adjuvant group a slightly increased number of 
IFNγ positive cells was detected, as compared to the other groups. The signal of 
mice immunized with 0.1 µg virosomes and c-di-AMP was very weak. In samples 
from PBS and Ag alone control groups, no spot formation above background for IL-4, 
IL-17 and IFNγ was observed. These results suggest a Th1/Th17 dominated immune 
response elicited by co-administration of at least 0.5 µg H5N1 virosomes and c-di-
AMP. 
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Fig. 47: Cytokine profiles of splenocytes after i.n. immunization with H5N1 virosomes and c-di-AMP. 
BALB/c mice were immunized three times with different dosages of H5N1 virosomes + c-di-AMP by i.n. route. 
Spleens were pooled and ELISpot assays for IL-4, IL-17 and IFNγ were performed. Each bar represents the mean 
of six wells plus SEM. *: p<0.05; **:p<0.01; ***:p<0.001; compared to H5N1 alone. n=5 
 
On the other hand, the production of IL-4, IL-17 and IFNγ is not unique to Th cells. 
Thus, it had to be confirmed if Th cells were indeed the source of the detected 
cytokines. This was achieved by the establishment of a multicolor FACS staining 
panel to characterize Ag specific immune responses from in vivo samples. The panel 
had to fulfill the two following tasks: (i) identification of all Th subsets and (ii) 
characterization of polyfunctional CD4+ T cells, which have been shown to play an 
important role in conferring protection against infections. Polyfunctional CD4+ T cells 
are characterized by their ability to produce at least two out of the three cytokines IL-
2, IFNγ and TNFα. To match these requirements it was necessary to set up a 
staining with nine different markers: Live/Dead, CD3, CD4, CD8, IL-2, IL-4, IL-17, 
IFNγ and TNFα. This combination of markers offers the possibility to measure also 
CD8+ T cell cytokine responses. The successful establishment of a staining protocol 
with working combinations of markers and fluorochromes is a powerful tool for T cell 
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analysis. This rendered possible the analysis of Ag specific cytokine profiles of 
restimulated CD4+ T cells from the mice immunized with H5N1 virosomes co-
administered with c-di-AMP. Almost no IL-4 producing cells were detected among all 
groups (Fig. 48). Only in the groups receiving virosomes co-administered with c-di-
AMP Ag specific responses were observed, as demonstrated by detection of 
intracellular IL-2, IL-17 and IFNγ. As compared to IL-2 and IL-17 producing cells (both 
about 0.3%), only few cells were positive for IFNγ (about 0.1%). On the other hand 
TNFα production was detected in all samples, but only in the groups which received 
Ag plus adjuvant the TNFα fractions were increased in Ag restimulated samples. 
Between cells from different virosome immunization groups, no significant differences 
with respect to cytokine responses were observed.  
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Fig. 48: Cytokine profiles of splenocytes after i.n. immunization with H5N1 virosomes and c-di-AMP. 
BALB/c mice were immunized three times with different dosages of H5N1 virosomes + c-di-AMP by i.n. route. 
Spleens from three animals per group were separately restimulated with H5N1 virosomes and stained for viability, 
CD3, CD4, CD8, IL-2.IL-4, IL-17, IFNγ and TNFα and analyzed by FACS. Each bar represents the mean of three 
mice plus SD. *: p<0.05; **:p<0.01; ***:p<0.001; unstimulated compared to Ag-restimulated. n=5 
 
To characterize polyfunctional CD4+ T cells, the profiles of cytokine secreting cells 
were analyzed by Boolean gating to identify cells producing combinations of IL-2, 
IFNγ and TNFα. In control groups receiving PBS or virosomes alone, almost no 
double or triple cytokine producing cells were detected (Fig. 49). Cells positive for 
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two cytokines were found in comparable numbers in all four groups immunized with 
Ag and adjuvant. The lowest percentages were detected in the 0.1 µg group and 
highest frequency in the 0.5 µg group. The double positive cells produced mainly IL-2 
in combination with TNFα, whereas the two other combinations of co-production were 
observed only in few cells. The production of all three was only detected at a 
maximum of 0.03% of viable, CD3+ CD4+ CD8- cells in mice immunized with the 
highest virosome dosage. In groups immunized with 0.1 or 2.5 µg of virosomes co-
administered with c-di-AMP only 0.01% of triple positive cells were observed, 
whereas in the 2.5 µg group a mean value of about 0.02% was measured. 
 
This analysis of cytokine profiles demonstrated that the immunization with H5N1 
virosomes co-administered with c-di-AMP induces not only normal Th responses, but 
also polyfunctional CD4+ T cells. However, an Ag dose dependent effect was not 
observed. 
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Fig. 49: Analysis of polyfunctional T cells after i.n. immunization with H5N1 virosomes and c-di-AMP. 
Viable and polyfunctional CD4
+
 CD8
-
 T cells were identified by Boolean gating on double or triple producers of IL-
2, IFNγ and TNFα shown in Fig. 48. Each bar represents the mean of three mice plus SD. *: p<0.05; **:p<0.01; 
***:p<0.001; unstimulated compared to Ag-restimulated. 
 
To check whether immunization with H5N1 virosomes at different doses and co-
administration with c-di-AMP as adjuvant is able to protect against infection, the 
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remaining animals of each group were challenged by i.n. route with the H5N1 
influenza virus. On the following 6 days the weight and general health of each mouse 
was monitored twice a day. Animals were sacrificed if they showed weight reduction 
of 25%, as compared to the starting weight. Mice immunized with PBS or virosomes 
alone died within 3 or 4 days post challenge (Fig. 50). Only one mouse of the PBS 
control group showed no symptoms of infection at all. Animals immunized with 0.5, 
2.5 or 7.5 µg of virosomes plus c-di-AMP were fully protected and only mild transient 
weight loss in the first days was detected (data not shown). In the group which 
received the lowest Ag dose during immunization, every third animal died or had to 
be sacrificed. Also the surviving animals of this group showed more severe 
symptoms of acute influenza infection, such as weight loss and scrubby hair. 
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Fig. 50: Survival of immunized mice after i.n. H5N1 virus challenge. Eleven BALB/c mice per group were 
immunized three times with different dosages of H5N1 virosomes + c-di-AMP by i.n. route and subsequently i.n. 
challenged with lethal dose of the genetically modified H5N1 virus strain NIBRG-14. Animals either died or were 
sacrificed when their weight loss was higher than 25% respect to the starting value. 
 
As an overall result for the immunization and challenge studies with H5N1 virosomes 
and c-di-AMP it has to be stated that in this model no dose dependent effects on Th 
polarization were observed. However, the results clearly demonstrated that 
vaccination with reduced Ag dose elicits strong immune responses which are 
protective in a challenge setting. The lack of dose dependent effects suggests that 
the experimental setting was suboptimal. This might be explained by two factors, (i) 
the strong induction of Th17 cells triggered per se by i.n. vaccination [142], and (ii) 
the stimulation of Th17 polarization by c-di-AMP [200, 201]. These two factors can 
lead to a situation in which Th17 polarization is already optimal and cannot be further 
increased by the reduction of the antigen dose. 
Results 
91 
 
6.3 Mechanism of Th17 differentiation blockage by NKT cells after 
stimulation with α-galactosylceramide 
As described in the introduction, Th17 immune responses are not always beneficial 
for the host. Beside autoimmune and inflammatory diseases, Th17 cells have been 
associated with non-optimal immune responses when induced following infection with 
certain pathogens (see 2.1.4 and 2.3). Thus, it would be helpful not only to induce 
Th17 polarization, but also to shut it down at will. It is known that αGC activates NKT 
cells and polarizes the immune response towards the Th2 phenotype while blocking 
Th17 induction. However, there is a paucity of knowledge on the underlying 
mechanisms. The elucidation of these molecular events would facilitate the 
exploitation of αGC as immune modulator, as well as provide hints on potential 
molecular targets for immune intervention. Thus, the second part of this work was 
focused on dissecting the mechanisms leading to the blockage of Th17 polarization 
after immunization with αGC as adjuvant. For the studies presented in the following, 
a pegylated form of αGC (αGCPEG) was used, which shows enhanced solubility and 
immune stimulatory activity [193].  
 
In the first experiment, the influence of different adjuvants co-administered with OVA 
via i.n. route on the elicited Th17 response was investigated. Curdlan and c-di-AMP 
are known to be strong inducers of Th17 cells, whereas the other used adjuvants 
lead to moderate IL-17 responses ([142, 201, 219, 220]). The animals were 
immunized and subsequently boosted on day 14 and 21. After a total of 42 days, the 
number of IL-17 secreting splenocytes was analyzed by performing ELISpot assays. 
The groups immunized with Curdlan and c-di-AMP displayed a high frequency of IL-
17 producing cells, as compared to the groups where only weak Th17 polarization 
was detected (Fig. 51). Beside the negative control groups, only αGCPEG did not 
induce Th17 cells at all. The absence of Th17 cells in αGCPEG immunized mice is 
remarkable since i.n. immunization should always lead to increased Th17 immune 
responses [142].  
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Fig. 51: αGCPEG blocks induction of Th17 immune responses after i.n. immunization. C57BL/6 mice per 
group were immunized with OVA co-administered with different adjuvants via i.n. route for a total of three times in 
21 days and sacrificed after a total of 42 days. Splenocytes pooled for every group were restimulated with OVA in 
ELISpot assay to detect IL-17 immune responses. Shown are the spot forming units per 10
6
 cells with subtracted 
background. Each bar represents the mean of 5 samples plus SEM. *, statistically significant (p<0.05). n=5 [221] 
 
To investigate whether the previously described activation of NKT cells by αGCPEG 
is responsible for the observed effect, an in vitro proliferation assay with sorted naïve 
CFSE-labeled OTII cells and DCs was performed. The cells were stimulated with 
OVA-peptide AA323-339 under Th17 polarizing conditions in the presence or 
absence of sorted NKT cells. To the samples either αGCPEG or BPPcysPEG as 
control was added. After 4 days of culture cells were restimulated, stained for IL-17 
and analyzed by FACS. The samples without addition of NKT cells showed a strong 
induction of IL-17 producing cells, independently of the added adjuvant (Fig. 52A). 
The addition of NKT cells led to a slight reduction of Th17 frequency in samples 
where BPPcysPEG was added (from 31% down to 9%). In contrast, in samples 
cultured in the presence of αGCPEG the polarization to Th17 cells was completely 
blocked. Only 0.4% of cells produced IL-17 in the presence of NKT cells, as 
compared to 27% in the absence of NKT cells. To clarify if this blockage was 
mediated by direct cell to cell interaction with NKT cells or by soluble factors released 
by activated NKT cells, in vitro proliferation assays with conditioned culture medium 
were performed. To OVA-peptide stimulated co-cultures of sorted CD4+ naïve CFSE-
labeled OTII cells and DCs supernatants from 24 h cultures of DCs plus αGCPEG, 
either in the presence or absence of NKT cells, were added. In samples where 
conditioned medium from cultures without NKT cells was added, 27% of divided 
CD4+ T cells produced IL-17, whereas the addition of NKT co-culture supernatants 
led to a complete blockage of Th17 differentiation (Fig. 52B). 
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Fig. 52: NKT cells block Th17 differentiation in vitro by soluble factors. Sorted naïve CD4
+
 T cells from OTII 
mice were labeled with CFSE and co-cultured with DCs under Th17 polarizing conditions in the presence of OVA-
peptide AA323-339. Cultures were supplemented either with αGCPEG or BPPcysPEG. After 4 days cells were 
restimulated and analyzed for IL-17 production by FACS. (A) To some cultures sorted NKT cells were added 
(right panels). (B) Cultures were supplemented with supernatants collected from 24 h cultures of DCs in the 
presence of αGCPEG (left panel) or co-cultures of DCs and NKT cells in the presence of αGCPEG (right panel). 
Shown are the dot plots from representative samples for each condition. [221] 
 
These results pointed to the fact that soluble factors released by NKT cells are 
responsible for the absence of Th17 cells. To identify these soluble factors, the levels 
of IL-4, IFNγ and IL-2 were measured by ELISA 24 h after the co-culture. As in the 
previously described experiments, naïve CD4+ OTII cells and DCs were co-cultured 
either in the presence or absence of NKT cells and with the addition of αGCPEG or 
BPPcysPEG. Cells cultured with αGCPEG showed high levels of IL-4 and IFNγ, 
which were dramatically decreased when NKT cells were present (Fig. 53A). The 
supernatants from samples incubated with BPPcysPEG showed only low levels of IL-
4, but high levels of IFNγ when NKT cells were added. No remarkable differences 
between the used adjuvants were observed when comparing IL-2 levels. In both 
cases relatively high IL-2 levels were detected and a small decrease of IL-2 
concentration was observed when NKT cells were present. 
 
Neutralizing Abs against IL-4 and IFNγ were used in subsequent experiments to 
check if the observed differences in these cytokine levels were responsible for the 
impaired Th17 differentiation. The neutralizing Abs were added single or combined to 
the above described in vitro proliferation assays, whereas no Abs were added to 
control wells. In the controls the induction of IL-17 producing cells was blocked by the 
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presence of NKT cells (Fig. 53B). This effect was weaker in the presence of αIL-4 
and especially αIFNγ, which led to 1.4% or 4.3% of Th17 cells respectively. However, 
only the combination of both neutralizing Abs almost restored the Th17 polarization in 
the presence of NKT cells to the level observed in the absence of NKT cells. In 
summary, the presented in vitro experiments clearly demonstrated that the blockage 
of Th17 induction in the presence αGCPEG is mediated by NKT cells releasing IL-4 
and IFNγ. 
 
 
Fig. 53: NKT cells block Th17 differentiation by secretion of IL-4 and IFNγ. (A) Sorted naïve CD4
+
 T cells 
from OTII mice were co-cultured with DCs under Th17 inducing conditions in the presence of OVA-peptide 
AA323-339. Cultures were supplemented with αGCPEG or BPPcysPEG in the presence or absence of NKT cells. 
Supernatants were collected after 24 h and the levels of IL-4, IFNγ and IL-2 were measured by ELISA. (B) Sorted 
naïve CD4
+
 T cells from OTII mice were stained with CFSE and then co-cultured with DCs under Th17 inducing 
conditions in the presence of OVA-peptide AA323-339 and αGCPEG. To some cultures NKT cells (right panels) 
and neutralizing Abs against IL-4 and/or IFNγ were added. Cells were restimulated after 4 days and analyzed for 
IL-17 production by FACS. [221] 
 
To further prove these observations, in vivo experiments with Jα281 KO mice which 
lack NKT cells were performed. C57BL/6 and Jα281 KO mice were immunized by i.n. 
route with OVA co-administered with αGCPEG. C57BL/6 control groups were 
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immunized with PBS, OVA alone or OVA plus BPPcysPEG. The animals were 
boosted on day 14 and sacrificed after a total of 28 days. Th17 induction in 
splenocytes was accessed by IL-17 ELISpot (Fig. 54). In C57BL/6 mice immunized 
with PBS or OVA alone almost no IL-17 positive cells were detected, whereas the co-
administration of OVA and BPPcysPEG led to a moderate IL-17 response. The 
application of OVA in combination with αGCPEG resulted in only few IL-17 positive 
cells in C57BL/6 mice, but in high numbers in Jα281 KO mice. With these results, 
NKT cells have been shown to be responsible for αGCPEG induced blockage of 
Th17 polarization also in vivo. 
 
 
Fig. 54: NKT cells block Th17 differentiation after i.n. immunization in vivo. Five C57BL/6 or Jα281 KO mice 
per group were immunized with OVA plus αGCPEG via i.n. route and boosted after 14 days. Control groups 
received PBS, OVA alone or OVA plus BPPcycPEG. After a total of 35 days animals were sacrificed and IL-17 
ELISpot with group pooled splenocytes was performed. Shown are the spot forming units per 10
6
 cells with 
substracted background. Each bar represents the mean of 5 samples plus SEM. *, statistically significant 
(p<0.05). [221]  
 
Based on the described results the interesting question came up, if the αGCPEG 
mediated blockage of Th17 cells caused by NKT cells can be used to attenuate 
strong Th17 immune responses when co-administering αGCPEG with a Th17 
polarizing adjuvant. To answer this question, C57BL/6 mice were immunized with 
OVA co-administered with αGCPEG, LPS, Curdlan or combinations of these immune 
stimulators. The animals were boosted on day 14 and 21 and sacrificed after a total 
of 42 days. The Th17 immune response was measured by IL-17 ELISpot from group 
pooled splenocytes. Control groups immunized with PBS or OVA alone showed no 
cells positive for IL-17 and also the co-administration of OVA and αGCPEG did not 
lead to a Th17 induction. The immunization with OVA plus LPS induced a moderate 
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IL-17 signal, which was significantly reduced when αGCPEG was added to the 
formulation (Fig. 55). The same dampening effect was observed when αGCPEG was 
co-administered with Curdlan. The very strong Th17 immune response induced by 
Curdlan alone was reduced to a moderate level. These observations gave evidence 
that αGCPEG is a promising candidate immune modulator, since it cannot only 
completely block Th17 induction when administered as adjuvant, but also fine tune 
the immune response when co-administered with other adjuvants.  
 
 
Fig. 55: αGCPEG efficiently modulates the effect of other adjuvants. Five C57BL/6 mice per group were 
immunized with OVA co-administered with different combinations of LPS, Curdlan and αGCPEG via i.n. route and 
boosted 2 times. After a total of 42 days animals were sacrificed and IL-17 ELISpot with group pooled splenocytes 
was performed. Shown are the spot forming units per 10
6
 cells with subtracted background. Each bar represents 
the mean of 5 samples plus SEM. *, statistically significant (p<0.05). [221] 
 
To sum up, this study identified the release of IL-4 and IFNγ by αGCPEG stimulated 
NKT as the underlying mechanism of Th17 blockage when administering αGCPEG 
as adjuvant. We further demonstrated that αGCPEG cannot only completely shut 
down Th17 immune responses, but even fine-tune Th17 induction when co-
administered with other adjuvants. 
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7 Discussion 
Vaccines should promote strong immune responses, including a robust 
immunological memory, thereby protecting against potential future encounters with 
pathogens. Currently available vaccines mostly trigger Th2 dominated immune 
responses with poor induction of CTLs [222, 223]. Thus, vaccine development efforts 
were focused on the development of tools and strategies to promote efficient Th1 
and CTL responses [165, 167, 173, 186, 222]. Following the recent discovery of 
Th17 cells, the understanding of the role played by this T cell subset in chronic 
inflammatory and autoimmune diseases was one major aim of research. In fact, 
during the development and testing of modern vaccine, Th17 cell induction has not 
been truly considered or was even disregarded. Nevertheless, a considerable body 
of experimental and clinical evidence strongly supports a prominent role of Th17 cells 
during infection. For example, the importance of inducing Th17 responses for 
efficient clearance has been lately shown for pathogens as Candida albicans, 
Klebsiella pneumoniae or the influenza virus [116, 123-125], whereas Th17 induction 
might be harmful during Borrelia infection [224]. 
 
It is important to consider that the induction of the inappropriate Th phenotype 
against a certain pathogen following vaccination can lead to higher susceptibility, 
severe health problems or even death. While BALB/c mice are unable to control a 
Leishmania major infection due to stimulation of a Th2 dominated immune response, 
C57BL/6 mice mount a protective Th1 response (see also section 2.1.3). For Th1 
and Th2 cells it was already described under which conditions (e.g. Ag dosage and 
cytokine milieu) their differentiation is induced [67-69, 82, 83]. In contrast, our 
knowledge about Th17 cells and their induction is rather fragmentary. For example, 
Purvis and co-workers recently showed the induction of Th17 cells at low TCR 
stimulation [151]. However, the results of this study are in contrast to other studies 
reporting Th17 induction following strong TCR stimulation [149, 150]. So far, no 
explanation was found for these contradictory results. One reason might be that 
different experimental models and methods were used in these studies. The study 
that showed Th17 polarization as a result of low TCR stimulation was performed 
mostly using human cells stimulated with either αCD3 Ab or super antigen, and it was 
based only on in vitro results. Both stimulation methods differ from the natural 
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process of TCR binding to peptide Ags presented by MHC class II molecules. This 
can in turn lead to abnormal T cell behavior, due to the triggering of unusual signaling 
pathways [152]. Accordingly, it has still to be proven if the results of this study are 
reproducible using a peptide Ag and/or performing in vivo experiments. In contrast, 
the need of a strong stimulus for Th17 induction described by Gomez-Rodriguez et 
al. and Iezzi et al. was observed in the murine system. While Gomez-Rodriguez 
performed only in vitro experiments using αCD3 Ab for stimulation, Iezzi performed 
both in vitro studies using only TCR transgenic cells stimulated by the corresponding 
Ag and in vivo experiments using a very limited range of Ag concentrations. 
However, the elicitation of strong Th17 immune responses following strong 
stimulation is not in agreement with the strong Th17 immune responses always 
obtained after i.n. application of the Ag. In fact, i.n. administration is normally linked 
to a poor Ag uptake, thereby leading to a reduction of the active Ag dose [142]. 
 
In this work, in vitro experiments were combined with in vivo adoptive transfers and 
immunization experiments using a total of three different TCR transgenic and two 
wild type mouse strains to get broader and deeper insights into the polarization of 
Th17 cells depending on the stimulation strength. In addition, the influence of TCR 
affinity to Ags presented by MHC class II on Th polarization was also taken under 
account, since in this regard no experimental data were available until now. The 
results discussed in detail in the following give direct answers to some of the pending 
questions and contribute to a better understanding of Th polarization process. For 
validation of the new findings, low dose immunizations using H5N1 virosomes 
followed by viral challenge were performed. Since not only the induction but also the 
controlled blockage of Th17 cells is interesting for vaccinations, the last part of this 
thesis was focused on the mechanism of Th17 blockage by αGCPEG. 
 
7.1 Ag dose dependent Th17 induction differs in DO11.10 and OTII mice 
In the present work, DCs and T cells were incubated for the whole in vitro 
proliferation assay in the presence of the Ag. This procedure led to more robust data 
as compared to those obtained when DCs were pulsed with Ag only for 3 h. Most 
probably, the washing steps following DC pulsing were the reasons for the observed 
variations between the single experiments as strong variations in the DC numbers 
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were observed after the washing. As demonstrated by experiments under controlled 
conditions, ratios the DC to T cell ratio was crucial for the final outcome (Fig. 27-Fig. 
29). The Ag dose dependent induction pattern of Th1 and Th2 polarization for cells 
from DO11.10 and OTII mice demonstrated that these two mouse strains mount 
similar Th responses. In most experiments Th1 as well as Th2 cells were induced 
preferentially at low to intermediate Ag dosages, which is in contrast to what was 
published before [82]. Constant et al. described Th1 polarization at intermediate to 
high Ag doses, whereas Th2 cells were observed at low dosages [82]. Despite 
differences in the experimental model and range of Ag used, one potential 
explanation is that the starting T cell population was less pure and characterized in 
the previous study as a result of the technical limitations in 1995. Therefore, it cannot 
be excluded that pre-activated or memory cells against different Ag were used for the 
experiments. It is known that memory cells can be activated independently of the 
presence of their specific Ag by cytokines, especially IL-2 [225]. 
 
Since in the present work only minor differences between the two mouse strains 
were observed in terms of Th1 and Th2 induction, the fundamental difference in Ag 
dose dependent induction of Th17 cells in these strains was quite surprising. 
DO11.10 cells differentiated to Th17 phenotype in the presence of low or high Ag 
concentrations, whereas OTII cells showed a peak of Th17 induction only at high Ag 
doses. The observed polarization towards Th17 phenotype at high doses in both 
strains is in line with the two studies named before, especially when only the Ag 
concentration range used in the study by Iezzi et al. is taken under consideration. 
There, cells were stimulated with peptide concentrations between 10 and 10000 nM. 
However, in the recent work the low dose peak detected for DO11.10 cells was 
elicited by Ag concentrations lower than 10 nM. Thus, it is possible that this 
observation was missed by Iezzi et al., since they did not titrate the Ag dose low 
enough in their experiments. However, this does not explain the differences observed 
between the mouse strains. Thus, further experiments to investigate the impact of 
culture conditions and OVA-peptide affinity of DCs were performed to understand this 
phenomenon. As described in the introduction (2.1.4), the addition of IL-6 and TGFβ 
to cultures induces enhanced Th17 polarization. These Th17 inducing conditions 
especially increased the Th17 polarization at intermediate and high Ag doses in both 
strains. Therefore, the low dose peak of Th17 polarization observed in DO11.10 cells 
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under normal conditions (full RPMI medium without addition of cytokines) was in 
most experiments very weak as compared to the high dose peak when Th17 
inducing conditions were used. The strongest change of Th17 levels at high Ag 
concentrations was also observed in the study of Iezzi et al. when Th17 polarizing 
cytokines were added. An Ag dose dependent influence of polarizing cytokines was 
already reported in the development of Tregs [35]. The same was true for the 
absence of Th1 and Th2 cells under Th17 polarizing conditions [226]. 
 
Like the addition of polarizing cytokines, the neutralization of IL-2 alone or in 
combination with neutralization of IL-4 and IFNγ also resulted in a similar enhancing 
effect on Th17 polarization. IL-2 has been shown to be essential for Th1 and Th2 
development, while it blocks Th17 differentiation [91, 227, 228]. Therefore, 
neutralization of IL-2 enhances Th17 polarization directly, as well as indirectly by 
inhibiting Th1 and Th2 polarization. This last effect is mediated by decreased levels 
of IL-4 and IFNγ in the culture, which further facilitates Th17 induction. However, in 
both investigated mouse strains the general Ag dose dependent Th17 induction 
pattern did not change by the addition of neutralizing Abs. Thus, different levels of 
these cytokines could be excluded as reason for the observed differences under 
normal conditions. The increased Th17 polarization when Th17 inducing cytokines 
were combined with neutralizing Abs in the assays were observed in both strains 
only at intermediate to high Ag doses, but not at low dosages. As consequence, it 
can be hypothesized that highly polarizing conditions are only effective if at least 
intermediate Ag concentrations are present. In which extend these rather artificial 
conditions also occur in vivo, still needs to be investigated. 
 
It is known that also IFNβ can influence Th polarization and that BMDCs generated 
by the addition of GM-CSF are able to produce this cytokine [229, 230]. However, 
neutralization of IFNβ in the assays did not result in any effect, neither under normal 
nor under Th17 inducing conditions. This might be explained by low levels of IFNβ in 
the cultures, which were not measured during the experiments. 
 
As discussed before, it was determined that the DC to T cell ratio plays an important 
role in Th differentiation. Higher numbers of DCs can present more Ag and provide 
increased numbers of co-stimulatory molecules to T cells, which resulted in an 
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increased Th17 polarization under normal, but not under Th17 inducing conditions, at 
intermediate and high Ag concentrations. In experiments for this thesis with different 
DC numbers, an increase over the 1 to 5 ratio of DCs to T cells resulted only in a 
small increase of Th17 cells. This might be explained by a study from Hopken and 
co-workers where it was shown that beginning with ratios of 1 to 2, the T cells 
stopped to proliferate and switched to a tolerant state [231]. One reason for the 
absence of an effect under Th17 polarizing conditions might be the presence of a 
threshold in Th17 numbers that once reached could not be raised by a further 
increase of the DC numbers. This would be in line with the observation that the Th17 
frequency reached a maximum at 1235nM OVA-peptide under Th17 polarizing 
conditions. The influence of co-stimulatory molecules on Th17 differentiation was the 
target of intense investigation in the last years. It was reported that strong interaction 
between CD40/CD40L at high Ag doses mediates IL-6 secretion by DCs, thereby 
enhancing Th17 polarization [145, 150]. In addition, also for B7/ICOS, OX40/OX40L 
and TIM-1/TIM-4 interactions a stimulating effect on Th17 induction has been shown 
[232-236]. The interactions between CTLA-4/B7 and PD-1/PD-1L instead counteract 
Th17 polarization [236-238]. Controversial results have been published concerning 
the role of CD28/B7 interaction. While two studies reported the essential need of this 
co-stimulation for Th17 induction, other studies showed a negative effect on Th17 
polarization [107, 141, 236, 239, 240]. 
 
By the use of a third TCR transgenic mouse line it was demonstrated that Th17 
polarization at low Ag concentrations is not only a special phenomenon for DO11.10 
cells. Moreover, it was shown that Ag dose dependent Th1 and Th2 polarization of 
TCR-HA cells behaves similarly to what was reported by Constant et al. for their 
model [82]. In contrast to DO11.10 and OTII cells, Th17 inducing conditions 
increased Th17 polarization of TCR-HA cells exclusively in the presence of low Ag 
doses. This effect might be explained by a different affinity of the TCR or MHC class 
II molecule to the Ag, which would result in altered stimulation strength. 
 
The similar loading of OVA-peptide on BMDCs derived from BALB/c and C57BL/6 
demonstrated by using FITC-labeled OVA-peptide rules out a differential affinity of 
MHC class molecules from both strains as a reason for the observed differences 
between DO11.10 and OTII mice. Therefore, it is most likely that this phenomenon is 
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caused by different affinity of the TCRs to the OVA-peptide. This hypothesis has 
been explored by using of sequence altered OVA-peptides, but the obtained results 
were not conclusive. As previously described, alterations of AA position 335 and 336 
led to decreased proliferation rates of DO11.10 and OTII cells [215]. Unfortunately, 
the proliferation was that dramatically reduced, making it impossible to identify an 
effect of Th subsets. 
 
In summary, for each TCR transgenic mouse strain robust results for the Ag dose 
dependent Th17 induction were achieved. Beside some similarities, evident 
differences in Th17 polarization where observed between the mouse strains, which 
were most probably based on differential TCR affinity to the corresponding peptide 
Ag. These findings show that experiments performed with different TCR transgenic 
mouse models cannot always be extrapolated to other systems. This might explain 
some contradictory observations in published studies using different mouse models. 
To expand these observations, studies were performed in which differential affinity of 
the Ag to the TCR was ruled out by direct CD3 stimulation with αCD3 Ab. This 
method also allowed to study cells from wild type mice. 
 
7.2 Ag independent stimulation with αCD3 Ab induces Th17 polarization 
at low dose 
Näive CD4+ T cells from BALB/c and C57BL/6 wild type mice as well as from OTII 
mice were stimulated in vitro with different concentrations of αCD3 Ab to study Ag 
independent Th17 polarization. The cells from all three mouse strains differentiated 
especially at low αCD3 Ab concentrations towards the Th17 phenotype. Under Th17 
inducing conditions the highest Th17 numbers were detected at low αCD3 Ab 
concentrations. These findings clearly demonstrated that (i) there are no general 
differences between BALB/c and C57BL/6 concerning Th17 polarization, and (ii) a 
Th17 polarization is induced when the strength of stimulation is low. The observation 
of Th17 polarization in the presence of low αCD3 Ab concentrations is in line with 
recent findings in the human system [151]. In that study Th17 induction was also only 
observed when low αCD3 Ab concentrations where used for stimulation. 
Nevertheless, it has to be mentioned that a study published by Gomez-Rodriguez et 
al. showed induction of Th17 polarization only with high αCD3 Ab concentrations 
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[140]. A possible explanation for this contradiction might be the use of different 
protocols. While in the recent work RPMI medium was used, Gomez-Rodriguez et al. 
cultured their cells in IMDM medium. It has been reported that IMDM medium 
contains high amounts of aryl hydrocarbon receptor agonists which induce Th17 
polarization. It is possible that under these polarizing conditions Th17 induction only 
occurred in the presence of high stimulus concentrations. In addition, we observed 
similar effects when neutralizing Abs for IL-2, IL-4 and IFNγ were combined with 
Th17 inducing conditions (7.1).  
 
The observation that cells from wild type and OTII mice were polarized towards the 
Th17 phenotype only in the presence of low αCD3 Ab concentrations gives further 
evidence that the observed differences in Ag dose dependent Th17 induction 
between DO11.10 and OTII mice are based on different affinities of their TCRs to the 
OVA-peptide AA323-339. As a consequence of these results it has to be 
reconsidered to which extent and under which specific experimental conditions TCR 
transgenic mouse models are a valid tool to extrapolate to the natural in vivo 
situation. 
 
7.3 Adoptive transfer of TCR transgenic T cells to wild type recipient 
mice as a model to study TCR transgenic cells in vivo 
The adoptive transfer is a well-established tool for characterization of T cell activation 
in vivo, since TCR-transgenic mice are tolerogenic to their TCR specific Ag (reviewed 
in [241]). In the recent study adoptive transfer experiments were performed to 
analyze antigen dose dependent Th polarization of OTII cells in an in vivo setting, in 
comparison to the in vitro studies performed before. Intra footpad immunization and 
subsequent analysis of the triggered immune responses in pLNs 3 days after 
injection appealed as the most suitable technique to assess proliferation and cytokine 
production of the transferred cells. Therefore, it was rather unexpected that the 
animals of each group showed extreme variations in cytokine production when 
immunized with different dosages of OVA co-administered with Curdlan. Since the 
recovery and proliferation rates of transferred cells were comparable between the 
mice of each group, inaccurate injection of OTII cells or immunization solution can be 
excluded as a possible explanation for this high variability. One problem might have 
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been the use of the glucan molecule Curdlan as adjuvant, which is not soluble in 
water. Therefore, injection solutions containing Curdlan have to be well shaken and 
quickly injected to guarantee homogenous distribution of the adjuvant. It cannot be 
ruled out that the animals of each group received different amounts of Curdlan. It is 
important to take into account that the concentration of adjuvant directly influences 
Th polarization, as discussed in the next section (7.4). This means that for a constant 
read out, it would be favorable to repeat this experiment with larger group sizes or to 
use a water-soluble adjuvant (e.g. pegylation of Curdlan). Due to limitations of the 
donor mice numbers it was not possible to test this new approach. 
 
7.4 Immunization studies with OVA-peptide reveals Th17 polarization at 
low Ag dose 
To evaluate the efficacy of new vaccination strategies, experimental small animal 
models constitute a commonly used approach. However, until now only one study 
investigated Ag dose dependent polarization of Th17 cells using an in vivo mouse 
model [150]. In that study C57BL/6 mice were immunized with 20, 50 or 100 µg of 
glycoprotein (gp; AA61-81) of the Lymphocytic Choriomeningitis Virus (LCMV) co-
administered with CFA via s.c. route. While in mice immunized with 50 and 100 µg of 
Ag high numbers of Th17 cells were detected, almost no Th17 response has been 
observed in animals that received only 20 µg of peptide. Interestingly, when similar 
studies were performed during this thesis using OVA, robust Ag specific Th17 
responses were induced in mice immunized with low doses of OVA, independently of 
the application route. The observed differences might be explained by the different 
experimental design. In the present work mice were immunized using full-length OVA 
protein (i.e. mimicking normal conditions in the field following vaccination), whereas 
Iezzi et al. used a peptide Ag. Proteins are ingested and processed by APCs, which 
results in the formation of different peptide Ags that are presented on the cell surface 
in the context of MHC molecules [1]. In contrast, peptide Ags can directly bind to 
empty MHC class II molecules on the surface of APCs [242]. By this means, the 
nature of Ag influences the triggered signaling cascades in APCs, as well as their 
activation status. This leads to different stimulatory properties and, thereby, to 
different adaptive immune responses. Furthermore, it was reported for OVA that most 
T cell responses are elicited by the peptide AA323-339 [241, 243, 244]. Thus, OVA-
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peptide AA323-339 only adds to 4% of the total molecular weight of OVA and the 
number of stimulating moieties strongly differs when comparing full-length protein 
and peptide. Since Iezzi et al. used 20 µg of gp peptide as their “low” dosage it is 
possible that this dosage still provided strong stimulation. This might explain the 
observed differences. 
  
Another point to mention is the observed influence of the LPS dose on Th17 
polarization. High LPS concentrations co-administered with a medium OVA dose 
elicited similar Th17 polarization as low dose Ag co-administered with low dosages of 
LPS. DCs are activated by LPS, which in turn leads to up regulation of co-stimulatory 
molecules that often favors Th17 polarization, as discussed before (7.1). Interactions 
of Ag dose dependent effects and co-stimulation have been described for Th1 and 
Th2 cells [245]. In that study strong co-stimulation induced Th1 and Th2 responses 
only in the presence of high and low Ag doses, respectively. However, the 
observation of the present thesis that Th17 induction at higher Ag doses is 
dependent on high co-stimulation has not been reported before. 
 
Taking together the results obtained from in vitro and in vivo experiments, the most 
probable reason for the differences in Ag dose dependent Th17 polarization between 
DO11.10 and OTII mice is the existence of differences in the affinity of the TCR to 
the OVA-peptide AA323-339. Thus, TCR independent stimulation by αCD3 Ab as 
well as the immunization studies showed a preferentially induction of Th17 cells 
when low stimulation strength was applied. Another fact is that highly Th17 polarizing 
conditions, especially at high Ag doses induced strong Th17 polarization, whereas at 
low Ag doses almost no effect was observed. This clearly demonstrated that Th17 
polarizing conditions are Ag dose dependent. The observation that high LPS 
concentrations co-administered with high Ag dosage also polarized towards the Th17 
phenotype in vivo contributes to this finding. As a conclusion it can be formulated that 
Th17 polarization seems to be induced either by low stimulation strength in the 
presence of poor Th17 polarizing conditions or by high stimulation strength in the 
presence of strongly polarizing conditions (Fig. 56).  
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Fig. 56: Hypothetical model of Th17 induction depending on stimulation strength and polarizing 
conditions. 
 
This two component model would explain the contradictory results published before 
and could help to better control the induction of Th17 cells. Until now, all discussed 
experiments were performed with the model Ag OVA or αCD3 Ab. To validate if the 
obtained results can be exploited to control Th17 induction in a clinical setting, 
vaccination studies were performed using a vaccine formulation against influenza. 
 
7.5 Mice immunized with low H5N1 virosome doses show a Th1/Th17 
immune response protective against viral influenza challenge 
Despite several improvements in health care, infectious diseases still represent one 
of the major health problems worldwide. For example, one of the threats to mankind 
all over the world is the influenza virus. We are faced with two different settings of 
influenza occurrence: (i) the seasonal influenza which spreads every year in 
autumn/winter and (ii) the spontaneous unpredictable outbreaks of pandemic 
influenza. In case of seasonal influenza, viruses of the subtype class A or B spread 
which are especially dangerous for newborns, elderly and immune-compromised 
people [246, 247]. Although vaccines against influenza are available since the 1940s, 
between 1985 and 2009 in average almost 11,000 patients per year died in Germany 
due to influenza infections [248-250]. Worldwide 250,000 to 500,000 people are killed 
every year by seasonal influenza outbreaks [247]. The World Health Organization 
(WHO) established the “Global Influenza Surveillance Network (GISN)” which 
earmarks every year three influenza strains for incorporation in the next vaccine 
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formulation. The seasonal influenza vaccine is composed of two influenza A strains 
(H1N1 and H3N2) and one influenza B strain. The exact strains are chosen as a 
prediction of the upcoming flu season based on isolates from the season before 
[247]. This system of prediction has one major drawback as well as one major 
advantage. If the prediction by the GISN was wrong, the vaccine will provide only 
limited protection. Thus, a meta-analysis of 31 independent studies about seasonal 
influenza vaccines revealed an overall efficacy of 67-75%, whereas in some seasons 
the efficacy of vaccines dropped to 35% [246]. However, the advantage of the 
system is that the prediction of the most probable strains for the next season allows 
the industry to produce the vaccines in advance and to supply them to people of risk 
groups in sufficient amount before the flu season starts. Since the 1950s, influenza 
vaccines are produced by inoculating chicken eggs with the vaccination virus strains, 
which is a strongly time consuming process. Cell culture systems for virus production 
are under development but are not fully approved yet [251]. Nevertheless, vaccine 
production capacities are very limited, in 2008 the worldwide capacity for seasonal 
influenza vaccine production amounted to approximately 820 million doses [252]. 
Production time and capacities would be also one of the major problems in a 
spontaneous pandemic influenza outbreak since no vaccine can be produced in 
advance as it is the case with seasonal influenza. Calculations for the H1N1 
pandemic in 2009 came to the result, that it would take more than one year to 
produce 5 billion doses of a new vaccine, not taking under account the time needed 
to identify the virus strain and to develop the complete vaccine formulation [253]. To 
shorten the time needed for the development of such a vaccine and its approval by 
the authorities, industry and authorities developed the so called “mock-up” and 
“emergency” procedure for the case of a pandemic influenza outbreak. In this mock-
up procedure, a vaccine formulation with a virus strain that potentially cause a 
pandemic is developed and approved in advance. In case of a pandemic influenza 
outbreak, the virus strain of the already tested and approved mock-up vaccine is 
exchanged against the pandemic strain so that the final vaccine can be produced 
and used after short safety tests. In contrast, the emergency procedure applies after 
a pandemic has already been declared and shortens the approval time by authorities 
to about 2 month instead of the normal 7 month. A third way to facilitate the supply 
with a pandemic vaccine is the modification of an already approved seasonal 
influenza vaccine [254]. So far, all the described scenarios are based on the use of 
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full live-attenuated or inactivated/split viruses as Ag in the vaccine formulations 
whose production is time consuming. An alternative approach which would be faster 
and more elegant constitutes the use of virosomes as vaccine Ag [207]. For the 
production of virosomes only purified HA and NA molecules are necessary, which 
can be isolated from whole virus or fast and easy produced by recombinant 
expression systems [205, 255]. Finally, another approach to speed up the vaccine 
production is the reduction of needed Ag per vaccination dose, the so called dose 
sparing. This can be achieved by the addition of a powerful adjuvant to the 
formulation which stimulates the immune system and/or enhances Ag uptake and 
presentation [200, 256, 257]. 
 
As described in the introduction (2.1.3), vaccinations need to stimulate the 
appropriate Th phenotype for each pathogen in order to provide a protective immune 
response. In case of the influenza virus it is not yet fully elucidated which Th 
phenotype is needed. Adoptive transfer studies from S. Swain and colleagues proved 
that influenza specific CD4+ effector cells are sufficient to protect against otherwise 
lethal viral challenge. Protection was achieved when either an unsorted pool of 
influenza specific CD4+ effector or sorted influenza specific Th1 cells were 
transferred [258]. However, these experiments were performed in 2004, when Th17 
cells where not known yet. Thus, a potential role of Th17 cells was not investigated in 
this study, which demonstrated the need of Th1 cells for protection against influenza. 
More recent studies showed that beside Th1 induction, protective immune responses 
included also Th17 polarization [125, 259-261]. On the other hand, for H1N1 it was 
reported that IL17R KO mice were better protected against viral challenge and that 
high Th17 cell numbers were detected in patients with severe pathology after 
infection with the pandemic H1N1 virus in 2009 [262, 263]. Thus, the role of Th17 
cells in protective immune responses against influenza infections has to be 
investigated in more detail.  
 
The initial studies carried out in this thesis demonstrated that immunization with low 
doses of the model Ag OVA favors Th17 polarization. Thus, in the second part of this 
work it was investigated whether Ag dose dependent Th17 polarization can be also 
achieved by following a mucosal vaccination strategy using a pathogen relevant Ag, 
with or without co-administration of an adjuvant. Since influenza vaccines are a good 
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candidate for i.n. application and the role of Th17 cells in protective immune 
responses against the influenza virus needed further investigation, H5N1 virosomes 
were chosen as Ag. The protectiveness of the elicited immune response was tested 
by a subsequent viral challenge. As shown in the result section, also immunization 
with the lower dosages of H5N1 virosomes co-administered with c-di-AMP via i.n. 
route led to the induction of Ag specific Th1 cells and elicited strong Th17 
polarization. This resulted in protection against challenge with an otherwise lethal 
viral dose. 
 
The strong Ag specific proliferation of splenocytes derived from animals immunized 
with 0.5, 2.5 or 7.5 µg of HA equivalents of H5N1 virosomes co-administered with c-
di-AMP indicates a robust systemic induction of H5N1 specific cells by the used 
immunization protocol. This is in line with published studies showing the stimulation 
of local as well as systemic immune responses after i.n. vaccination, especially when 
c-di nucleotides are used as adjuvant [142, 201]. The analysis of the elicited Th 
subsets by ELISpot and FACS revealed a mixed Th1/Th17 dominated immune 
response, whereas Th2 cells were almost absent. These findings are in line with a 
recent study showing a Th1/Th17 dominated immune response following 
immunization with a trivalent influenza vaccine [261]. However, while in the ELISpot 
assays the number of IFNγ positive cells was slightly higher than the number of IL-17 
positive cells, FACS analysis revealed a 2-fold higher frequency of IL-17 positive 
cells, as compared to that of IFNγ positive cells. Furthermore, with the second 
method also in the samples from animals immunized with 0.1 µg H5N1 virosomes co-
administrated with adjuvant a clear Th17 polarization was detected, which was 
absent in the ELISpot assays. These differences could be explained by the fact that 
IFNγ can be produced not only by Th1 cells, but also by CD8+ T cells, NK cells, NKT 
cells, macrophages and DCs [221, 264-266]. Thus, with an ELISpot assay it is not 
possible to identify the source of the detected IFNγ, since only already secreted 
cytokines are measured. In contrast, when performing the multi-parametric FACS 
analysis only CD3+ CD4+ CD8- cells were analyzed for cytokine expression. In 
addition, by ELISpot cytokines produced by more than one cell can be detected as a 
“single” spot. Therefore, while the FACS analysis presents the “true” picture of the 
Th1 population induced following vaccination, the IFNγ signals detected by ELISpot 
analysis most probably derived also from non-Th cells. This in turn might explain the 
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reduced numbers of IFNγ producing cells observed by the FACS analysis. However, 
the elicited Th1 response was robust, and able to confer  protection against a lethal 
influenza infection. 
A possible explanation for the differences observed in mice immunized with lowest 
dosage of virosomes when comparing ELISpot and FACS data could be related to 
the different principles of signal measurement. ELISpot assays allow just the 
detection of cytokines already secreted, whereas FACS in addition allows the 
detection of not yet secreted cytokines. Most probably the lowest Ag dose only led to 
cytokine production but not secretion, as some kind of short term non secreted 
cytokine storage, like previously described [267-269]. The physiological role of this 
phenomenon is not known yet. However, as discussed later, the immune response 
triggered by 0.1 µg of virosomes was not able to protect all mice against viral 
challenge. 
 
Comparing the results obtained after immunizations with either OVA or H5N1 
virosomes as Ag, it has to be stated that the strongly increased induction of Th17 
phenotype at low Ag dose, as compared to medium and high Ag doses was only 
observed when mice were immunized with OVA. The use of virosomes as Ag 
stimulated very high numbers of Th17 cells at all used concentrations when co-
administered with adjuvant. However, it is unlikely that the observed phenomenon of 
low Ag dose Th17 induction is exclusively triggered by OVA, since in vitro 
proliferation assays with HA-peptide as Ag clearly demonstrated an increased 
induction of Th17 cells at low Ag concentrations. This finding was further confirmed 
when T cells were stimulated in vitro in an Ag independent manner by titrating αCD3 
Ab, thereby resulting in a Th17 polarization at low concentrations. More likely, the 
differences in Th17 polarization are based on the immunization strategy and/or the 
vaccine formulation. 
 
The immunizations with OVA were performed by s.c. or i.p. route, which do not favor 
the induction of a specific Th phenotype. Furthermore, the co-administration of LPS 
only leads to moderate Th17 responses by itself. In contrast, i.n. application and c-di-
AMP strongly favor the induction of Th17 cells [142, 200, 201, 207, 221]. Therefore, 
immunization of mice with H5N1+c-di-AMP by i.n. route stimulated about 4 times 
higher numbers of IL-17 secreting splenocytes, as compared to those observed 
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following vaccination of mice using OVA+LPS (400 and 100 IL-17 positive cells per 
1x106 cells, respectively). Although very strong Th17 responses were elicited, the 
health status of immunized mice was not affected (e.g. neither weight loss nor 
scrubby hair was observed). This is important since in patients with severe cases of 
H1N1infection outbalanced Th17 responses were observed that led to a cytokine 
storm with subsequent lung damage and respiratory failure [262, 270]. 
 
When co-administering medium concentrations of OVA with very high LPS doses, 
very strong Th17 responses were elicited. It is possible that the used dosage of c-di-
AMP co-administered with H5N1 virosomes had a comparable effect and was 
therefore masking a putative dose dependent effect on Th17 polarization. Another 
possibility could be that by the combination of Th17 inducing components in 
association with the i.n. application route some kind of physiological threshold of 
Th17 polarization was already reached at medium Ag dosages, which could not be 
breached by lowering the Ag dose, which would under normal conditions lead to a 
further increase of Th17 induction. If such a physiological threshold exists, it would 
be most probably controlled by Tregs, which are known to limit and balance Th17 
immune responses. This special ability of Tregs is already used for therapy of Th17 
linked inflammatory and auto-immune diseases [271-274]. To validate if this 
hypothesis explains the observed missing of increased Th17 polarization at low 
H5N1 doses, immunizations with different adjuvants and different application routes 
should be performed. Also the comparison of Treg populations after the two 
described immunization settings could provide new insights into Th17 biology. 
 
However, the characterization of the elicited Th phenotypes is not sufficient to judge 
the effectiveness of an immunization, since it has been reported for many pathogens 
(e.g. Mycobacterium ssp., Leishmania ssp. and influenza virus) that a highly 
protective immune response depends on so-called polyfunctional CD4+ T cells. 
These cells are characterized by their ability to secrete different combinations of the 
cytokines IL-2, IFNγ and TNFα and therefore play a vital role in orchestrating the 
adaptive immune response [48, 259, 275, 276]. The identification of these cells is 
only possible by multi-parametric flow cytometry, since the cytokines produced by a 
single cell have to be characterized simultaneously. The 9-color staining panel 
developed during this thesis was able to fulfill this task. Thus, in the present work it 
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was demonstrated that immunization with H5N1 virosomes co-administered with c-di-
AMP by i.n. route was able to induce polyfunctional T cells (Fig. 49). The population 
producing two cytokines was clearly dominated by TNFα and IL-2 double positive 
cells, whereas the other combinations where only present in minor fractions. These 
results are in line with recent findings showing a comparable distribution of 
polyfunctional T cells in mice immunized with purified influenza proteins co-
administered with c-di-GMP, another cyclic di-nucleotide exhibiting adjuvant 
properties [259]. Nevertheless, it has to be stated that the frequency of cells 
producing all three cytokines was lower in the present study, as compared to the 
results from Madhun et al. [259]. However, the number of polyfunctional T cells 
induced by H5N1 virosomes + c-di-AMP was sufficient to provide a protective 
immune response. Interestingly also in the group immunized with 0.1 µg virosomes 
and c-di-AMP polyfunctional T cells were detected. 
 
The subsequent challenge with a lethal dose of the influenza virus revealed that the 
immune response elicited by the lowest vaccination dose of H5N1 virosomes (0.1 µg) 
was sufficient to protect only 70% of the mice. This is in line with the observed low 
cellular responses and absence of cytokine secreting cells, indicating that the lowest 
Ag dose was not sufficient to trigger robust immune responses. In contrast, all 
vaccine formulations encompassing higher virosome dosages co-administered with 
c-di-AMP induced 100% protection against viral infection. The fact that already 0.5 µg 
of virosomes co-administered with c-di-AMP via i.n. route are sufficient to elicit a 
protective immune response are remarkable in the context of dose sparing, since 
recent studies reported the need of 5-7.5 µg H5N1 virosomes to induce robust 
immune responses following vaccination [277, 278]. Thus, the here presented 
combination of immunization strategy and vaccine formulation allows to reduce the 
amount of Ag needed to elicit full protective immunity by the factor 10 to 15, as 
compared to similar studies. This in turn would dramatically reduce the production 
time of sufficient lots of a vaccine in a pandemic influenza outbreak.  
 
In conclusion, it was demonstrated that by the combination of mucosal application 
route, a promising adjuvant candidate and low Ag dose immunization mixed 
Th1/Th17 immune responses were stimulated that were protective against a 
subsequent viral challenge. The strong Th17 responses which were elicited had no 
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negative consequences for the immunized animals. In fact, it seems that the Th17 
response rather contribute to the overall protective effect. However, it has to be 
investigated whether the described approach can be transferred to humans still. 
Nevertheless, the perspectives are quite promising as the single components of the 
presented immunization strategy are already approved for the use in humans (i.n. 
application [279]), have been tested in clinical trials (H5N1 virosomes [207]) or have 
been shown to stimulate not only murine but also human cells in vitro (c-di-AMP 
[201]). Concerning the potential risk of neurological side effects (Bell’s palsy) 
following i.n. vaccination, it is important to highlight that this was only seen in 
association with the use of AB moiety toxins and their derivatives as adjuvants (i.e. 
adjuvants for which specific receptors exist in neurons [280, 281]). Thus, the use of 
c-di-AMP as i.n. adjuvant might not represent any risk. In addition, we have assessed 
the activity of the adjuvant when administered by the sublingual route, which in turn 
should not comport any risk of retrograde homing to the central nervous system. 
Unpublished results from our group demonstrated a successful stimulation of robust 
immune responses following sublingual immunization with formulations containing c-
di-AMP, which were comparable to those obtained after i.n. application. 
 
7.6 Mechanism of Th17 differentiation blockage by NKT cells after 
stimulation with α-galactosylceramide 
As mentioned above, Th17 cells have been shown to play an important role in 
clearance of certain pathogens such as Candida albicans, Klebsiella pneumoniae or 
influenza virus [116, 123-125]. However, Th17 cells are also known to be harmful, as 
they are responsible for autoimmune diseases like RA, MS or IBD [100] and can lead 
to immune pathological reactions following infection, such as chronic inflammation 
after Borrelia infection [224]. These examples show the importance of controlling the 
induced Th phenotype when performing vaccinations. Thus, it would be helpful to 
have substances that can specifically trigger or block Th17 differentiation when 
added to vaccine formulations. Previous studies showed that immunization by i.n. 
route always results in strong Th17 responses, which can be either beneficial or 
unfavorable depending on the pathogen against which has to be vaccinated. This 
implies problems for this otherwise promising application route. The immunization 
experiments performed during this work clearly demonstrated that the Th17 
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phenotype induced by i.n. vaccination can be easily blocked by co-administration of 
αGCPEG as adjuvant. Furthermore, administration of αGCPEG not only blocks the 
stimulation of Th17 responses, but also modulates and fine tunes the strength of 
Th17 induction when combining it with other polarizing adjuvants. The observed 
blockage of Th17 cells is mediated by NKT cells. This is supported by the results of in 
vitro experiments in which NKT cells stimulated with αGCPEG shut down the 
generation of IL-17A producing CD4+ T cells, even under Th17 polarizing culture 
conditions. In addition, real-time PCR analysis revealed that NKT cells stimulated 
with αGCPEG also inhibit the production of IL-17F and down-regulate the expression 
of the Th17 specific transcription factor RORγ (data not shown). These results were 
confirmed by the in vivo studies using Jα281 KO mice, which lack functional NKT 
cells. In these animals an efficient Th17 differentiation was observed even after i.n 
immunization with αGCPEG as adjuvant. In wild type animals which received the 
same formulation, a Th17 immune response was absent. Furthermore, in vitro 
studies performed during this work, based on NKT cell co-cultures and the addition of 
neutralizing Abs, demonstrated that IL-4 and IFNγ released by NKT cells were 
responsible for the observed Th17 inhibition. Interestingly, the presence of IL-4 or 
IFNγ alone was sufficient to block the stimulation of Th17 cells. In contrast, 
simultaneous neutralization of both cytokines fully restored the Th17 response. Thus, 
the present work revealed for the first time the underlying mechanism of Th17 
blockage triggered by αGCPEG. It is remarkable that this blockage mediated by NKT 
cells is based on the same effects by which Th subsets influence each other’s 
induction. Namely, by the release of IL-4 and IFNγ rather than by any new mediators 
or cell-to-cell interactions. As this mechanism is already quite well understood, it will 
allow for a better prediction and targeted investigation of functionality and potential 
side effects of αGCPEG in order to develop this compound as a vaccine adjuvant. 
 
Another interesting point is the fact that NKT cells not only block the release of IL-17 
by inhibiting Th17 differentiation (see also [282]) but also produce IL-17A by 
themselves [283]. This finding seems to be contradictory to what was reported 
before, but it is consistent when looking at the chronology of events. In concert with 
other components of the innate immune system, NKT cells respond very fast after an 
encounter with a pathogen. Thus, they are an early source of IL-17A which promotes 
inflammation [284]. It can be hypothesized that later, when the adoptive immune 
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system starts to respond, NKT cells modulate the Th differentiation to prevent a 
potentially harmful over-induction of Th17 cells. In this context, a study from Lin et al. 
showed that early IL-17 production is needed to induce Th1 immune responses 
under certain conditions [285]. 
 
The ability of αGCPEG to inhibit Th17 differentiation could be also helpful to 
investigate if and in which extent Th17 cells are important for protection against 
certain pathogens. As discussed before (7.5), it is not yet fully clarified if a strong 
Th17 immune response is beneficial for protection against all influenza strains. Here 
αGCPEG could be used to selectively block the Th17 differentiation in an 
immunization and subsequent viral challenge, in a comparative analysis with Th17 
inducing adjuvants. An in depth knowledge about the influence of Th17 induction on 
the outcome of immune responses against pathogens is a crucial step for the 
improvement and de novo development of vaccines. 
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8 Conclusions and Outlook 
The studies performed in this thesis showed that the induction of the Th17 phenotype 
is not only influenced by the amount of Ag used for stimulation, but also by several 
other factors, such as the cytokine milieu and co-stimulation. Furthermore, Ag dose 
dependent Th17 polarization depends on the genetic background of the donor TCR 
transgenic animals to which the Ag is presented. This is most probably due to 
differences in TCR affinity to the Ag. In addition, Th17 induction in vivo also depends 
on the adjuvant used and specific dosage of both Ag and adjuvant. Taken together, 
from the outcome of the experimental work it can be hypothesized that Th17 cells are 
preferentially induced by low strength stimulation in the absence of polarizing 
conditions, as well as by strong stimulation in the presence of strong Th17 polarizing 
conditions.  
 
Intranasal immunization of mice with low dosages of a virosome-based vaccine 
against the influenza strain H5N1 co-administered with c-di-AMP induced protective 
immune responses characterized by a strong Th1 and Th17 polarization. Under 
these experimental conditions the Ag dose needed to elicit protective immunity could 
be reduced by a factor of 10-15 with respect to previous studies. This represents a 
considerable dose sparing effect. 
 
It would be of great interest to further investigate the differences observed between 
the transgenic mouse strains. To this end, a large library of mutated OVA-peptides 
could be used to investigate the impact of the TCR affinity to the Ag on Th17 
polarization exploiting surface plasmon resonance with Biacore technology. It would 
also be necessary to further validate the results obtained using OVA as Ag by 
repeating the experiments with influenza virosomes as Ag under less Th17 polarizing 
conditions. To this end, different application routes or adjuvants need to be included 
in the immunization protocols. 
 
Finally, for the development of vaccines, not only the induction of Th17 immune 
responses is of great interest, but also their specific blockage. During this work, 
secretion of IL-4 and IFNγ by NKT cells was identified to be responsible for blockage 
of Th17 cell induction by αGCPEG. These findings provide a better characterization 
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of the underlying mechanisms of adjuvanticity of αGCPEG and highlight its potential 
to tailor Th17 responses. Additional work will be required to define the true potential 
of αGCPEG in this regard, such as vaccination and challenge experiments using 
different infection models (e.g. Borrelia ssp.) for which the stimulation of a Th17 
immune response represents a drawback for the host. 
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